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ABSTRACT 
Background. Congenital atrioventricular block (CHB) is the most frequent manifestation of 
neonatal lupus which is attributed to anti-Ro/SSA and/or anti-La/SSB-mediated 
inflammation and subsequent fibrosis of the atrioventricular node. Despite the observation 
of a direct role for maternal antibodies in inducing CHB both in vitro and in vivo studies, the 
mechanisms involved remain unclear.  Currently no therapy is found to be effective in the 
treatment of 2nd and 3rd degree CHB induced by maternal antibodies; also because the 
rarity of the disease does not allow for controlled clinical trials.  
Objectives. To explore the role of anti-Ro52 antibodies in the pathogenesis of CHB by 
identifying of the epitope specificity of anti-p200 antibodies. To study in an animal model 
the effect on heart conduction system of the different doses of injected human IgG 
antibodies from a CHB patient. To evaluate the clinical efficacy and safety of a combined 
therapy protocol utilizing plasmapheresis, intravenous immunoglobulin (IVIG) and 
betamethasone and the effect of this treatment on anti-Ro52, anti-p200 and anti-La 
antibody levels. 
Materials and Methods. Laboratory methods: ELISA assay, circular dichroism 
spectroscopy and antibody purification. Procedure: antibody transfer by intra-peritoneally 
injection of purified IgG. Instrumental methods: fetal ecocardiography and 
electrocardiogram recordings. Treatment strategy: Six consecutive women diagnosed 
CHB underwent a combination therapy protocol composed of weekly plasmapheresis, 
fortnightly 1 g/Kg IVIG and daily Betamethasone (4 mg/day) throughout pregnancy. IVIG (1 
g/Kg) treatment in the neonates was begun at birth and administered every fifteen days 
until passive maternal antibodies became undetectable. Statistical analysis: Wilcoxon, 
Mann-Whitney U, two way ANOVA and Spearman’s tests; p<0.05 was considered as 
significant. 
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Results and Conclusion. Part I: The epitope specificity of anti-p200 antibodies was the 
position 233. We suggest that this antibody specificity might be a tool to identify high risk 
pregnancies for CHB. The results might contribute to identify antibody specificity closely 
associated with development of CHB and to provide the possibility to explore the role of 
this antibody in the pathogenesis of CHB.  
Part II: We developed an animal model for CHB by a simple technique of passive transfer 
of human IgG from a patient with a child with CHB. High levels (4 mg) of anti-SSA/Ro and 
anti-SSB/La antibodies induce bradycardia, atrioventricular time prolongation and a 
decreased cardiac performance. Whereas, low levels (2 mg) of these antibodies determine 
a decrease in cardiac performance.  
Part III: The obtained results from these case series are: a) the efficacy in treating 2nd 
degree CHB, and b) the safety of plasmapheresis and IVIG therapies. The low number of 
treated cases, the relatively short follow-up (mean 22.7 months ± 10.4 SD, range 12-42 
months) and the high cost of the procedure can all be considered limits.  
Part IV: Plasmapheresis reduces the levels of anti-Ro52, anti-p200 and anti-La antibodies. 
However, a decrease of antibody amounts in patients with the highest anti-Ro52 antibody 
levels has not been demonstrated. 
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RIASSUNTO 
Premesse. Il blocco atrioventricolare congenito (CHB) è la manifestazione più frequente 
del lupus neonatale. Esso è causato dal passaggio transplacentare degli anticorpi anti-
Ro/SSA e/o anti-La/SSB con successiva infiammazione e fibrosi del nodo 
atrioventricolare. Nonostante la dimostrazione di un ruolo diretto degli anticorpi materni 
nell'indurre CHB sia in vitro che in vivo, i meccanismi coinvolti rimangono poco chiari. 
Inoltre finora nessuna terapia è risultata efficace nel trattamento del CHB sia di secondo 
che terzo grado, anche perché la rarità della malattia non consente studi clinici controllati. 
Obiettivi. Studiare il ruolo degli anticorpi anti-Ro52 nella patogenesi del CHB attraverso la 
definizione della specificità epitopica degli anticorpi anti-p200. Sviluppare un modello 
animale per studiare l'effetto sul sistema di conduzione cardiaco degli anticorpi IgG 
purificati da una paziente con CHB fetale. Infine valutare l'efficacia clinica e la sicurezza di 
un protocollo di terapia combinato comprendente l’impiego di plasmaferesi, 
immunoglobuline per via endovenosa (IVIG) e betametasone, nonchè l'effetto di questo 
trattamento su i livelli degli anticorpi anti-Ro52, anti-p200 e anti-La. 
Materiali e Metodi. Metodi di laboratorio: ELISA, spettroscopia con dicroismo circolare e 
purificazione di IgG umane. Procedura sperimentale: trasferimento per via intra-
peritoneale degli anticorpi mediante l’iniezione di IgG purificate da una madre con CHB. 
Metodi strumentali: ecocardiografia fetale ed elettrocardiografia dopo la nascita. Strategia 
di trattamento: Sei donne diagnosticate con CHB sono state trattate durante la gravidanza 
con un protocollo di terapia di associazione composta da plasmaferesi settimanale, IVIG 
1g/kg a cadenza quindicinale e Betametasone giornaliero (4 mg). Inoltre, IVIG (1 g/kg) 
sono state somministrate ai neonati ogni quindici giorni subito dopo la nascita fino alla 
negativizzazione degli anticorpi materni passivi. Analisi statistica: Wilcoxon, Mann-Whitney 
U, ANOVA e Spearman tests. Il valore di p<0,05 è stato considerato significativo. 
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Risultati e Conclusioni. Parte I: La specificità epitopica dell’anticorpo anti-p200 è stata 
localizzata nella posizione 233. Tale epitopo potrebbe essere utile per identificare la 
specificità anticorpale strettamente associata allo sviluppo del CHB e costituire quindi uno 
strumento per individuare le gravidanze ad alto rischio per CHB. Inoltre potrebbe 
contribuire a chiarire il ruolo di questo anticorpo nella patogenesi del CHB. 
Parte II: Abbiamo sviluppato un modello animale del CHB con una semplice tecnica di 
trasferimento passivo di IgG umane purificate da un paziente con CHB fetale. Gli alti livelli 
(4 mg) degli anticorpi anti-Ro/SSA ed anti-La/SSB hanno indotto bradicardia, 
prolungamento dell’intervallo PR e una depressione delle funzione cardiaca nel animale. 
Invece, i bassi livelli (2 mg) hanno determinato solo una diminuzione della funzione 
cardiaca. In questo modo è stato dimostrato la patogenicità degli anticorpi anti-Ro/SSA ed 
anti-La/SSB sul sistema di conduzione cardiaco. 
Parte III: I risultati ottenuti da queste serie di casi sono i seguenti: a) l’efficacia nel 
trattamento del CHB di 2° grado, e b) la sicurezza della plasmaferesi e delle IVIG. Tuttavia 
il basso numero di casi trattati, e il follow-up relativamente breve (media 22,7 mesi ± 10,4 
DS, range 12-42 mesi), come anche l'alto costo della procedura possono essere 
considerati limiti. 
Parte IV: La plasmaferesi riduce i livelli degli anticorpi anti-Ro52, anti-p200 e anti-La. 
Tuttavia, un decremento significativo anticorpale non è stato dimostrato nelle pazienti con 
livelli molto alti di anticorpi anti-Ro52. 
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1. INTRODUCTION 
 
1.1 Neonatal lupus syndrome 
Neonatal lupus syndrome (NLS), is a passively acquired autoimmune disease caused by 
the transplacental transfer of maternal autoantibodies (anti-SSA/Ro and anti-SSB/La) into 
the fetal circulation (1). The woman may have Sjögren syndrome (SS), systemic lupus 
erythematosus (SLE) or undifferentiated connective tissue disease (UCTD), but may be 
also asymptomatic. NLS is characterized by cutaneous rash, cytopenias, cholestatic 
hepatitis and congenital heart block (CHB) (2). The NLS symptoms are transient, except 
CHB, and disappear when the maternal antibody levels have decreased in the neonate 
system at approximately 6-8 months (3). 
 
1.2 Congenital heart block 
CHB is the most common and severe manifestations of NLS which develops in the fetal 
heart in the absence of any major structural malformation and in the presence of anti-
SSA/Ro and anti-SSB/La maternal autoantibodies (4,5). CHB is considered congenital if 
diagnosed in utero or during the first 27 days of life (6). It is hypothesized that CHB 
progress gradually from a first-degree atrio-ventricular block (AVB) to a second-degree 
AVB and finally this could progress to the irreversible third-degree AVB (7). A third-degree 
AVB is a potentially lethal condition associated with high rate of fetal morbidity and 
mortality (2). However, antibodies and complement deposits together with signs of fibrosis 
and calcification are found in the conduction fetal system as well as in the entire 
myocardium (8-10), suggesting the potential involvement of maternal autoantibodies in 
other cardiac manifestations of CHB, such as myocardial inflammation, dilated 
cardiomyopathy, endocardial fibroelastosis, sinus bradycardia, and QTc prolongation 
rather than AVB  (11-14). 
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1.2.1 History  
 
Morquio was the first to describe, more than a century ago the rare defect of third-degree 
heart block in an infant (15). Subsequently, in 1928, Aylward reported the cases of heart 
block in 2 children whose mothers “suffered from Mikulicz’s Disease” (16). This clinical 
association begun strengthens by the 1970s, with reports of several children with heart 
block whose mothers had autoimmune diseases (17-19) but only in 1983 was observed 
that sera from mothers whose children have heart block contain antibodies to SSA/Ro 
ribonucleoproteins (20, 21). Further clinical refinement demonstrated that is the heart block 
in an otherwise normal structurally heart, identified in utero, not in childhood, which is 
associated with maternal autoantibodies (22). Hence, CHB, a lifelong disability previously 
of interest only to cardiologist, became an important model of passively acquired 
autoimmunity. However, still now after five decades, this rare disease is underdiagnosed 
and the mothers, most of the time do not receive the adequate counseling. 
 
1.2.2 Epidemiology  
CHB developed in the presence of maternal autoantibodies associated with the rheumatic 
diseases such as SS, SLE or UCTD, but the mother of an affected child may also be 
asymptomatic. CHB is a rare disease with an incidence of 1:15.000-1:20.000 of cases for 
year (23) which is most commonly developed during weeks 18 to 24 of pregnancy, even 
rather it can be manifested until 30 weeks of gestation. CHB occur only in 1–2% of anti-
SSA and/or anti-SSB positive primigravid women (24) but carries a recurrence rate around 
20%, in subsequent pregnancies despite the persistence of the autoantibodies (25). The 
development of third-degree CHB requires insertion of a pacemaker after birth. Despite 
pacemaker placement, ~10% of these children develop cardiomyopathy (26). Moreover, 
the cardiomyopathy due to inflammatory immune damage causes 40–60% of infant 
morbidity and 20–30% of mortality, mostly fetal and neonatal deaths (27). Long-term 
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follow-up of children with CHB to the age of 10 years has shown mortality rates of 20–30% 
and morbidity rates of ~35%, with an 80% cumulative probability of survival at 3 years of 
age (26). Recently, it has been described an association of the development of CHB with 
maternal age and the seasons (4). 
 
1.3 Autoantibodies associated with congenital heart block 
 
The relationship between maternal antibodies against the SSA/Ro and SSB/La antigen 
and CHB is well established, and the antigen contains several components to which 
rheumatic patients develop autoantibodies. 
 
1.3.1 The SSA/Ro and SSB/La antigens  
 
The SSA/Ro antigen consists of a 52 kDa protein (Ro52) and a non-homologous 60 kDa 
protein (Ro60) (Figure 1).  
 
 
 
 
 
 
 
 
Figure 1. A) SSA/Ro and SSB/LA antigens; B) Fluoroscopic pattern on HEp-2000 cell of 60 kD anti-SSA/Ro  
 
Ro52 belongs to the tri-parted motif (TRIM) family of proteins (28), characterized by a 
RING domain (29), a B-box type 2 motif (30) and a coiled-coil region (Figure 2). 
 
 
A B 
Ro52 
Ub 
Ro60 
  La 
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Figure 2. The common structure of TRIM proteins. 
Several studies have shown that TRIM family members act as an E3 ubiquitin ligases 
involved in the ubiquitination process (31-34). Ubiquitination process (Figure 3) is a post-
translational modification mechanism of the proteins by ubiquitins, small regulatory 
proteins found in all eukaryotic cells from plants to mammals, leading either to proteolysis 
in the proteasome, internalization from membranes or functional alteration (35-37). The 
protein ubiquitination is a multi-step process that involve three enzymes; first, ubiquitin is 
activated by ubiquitin-activating  enzyme (E1), then is transferred to a ubiquitin-conjugating 
enzyme (E2) followed by a ubiquitin ligase (E3) which interacts directly with E2 enzyme 
and its substrate and mediates the transfer of ubiquitin from E2 to a target protein (38). 
Figure 3. Ubiquitination process. 
The process can be repeated until a short chain is formed, with three or more ubiquitin 
molecules usually targeting the protein to the proteasome. In the proteasome, 
RING B-Box Coiled-coil 
 
B30.2 
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polyubiquinated proteins are degraded. The role of Ro52 as an E3 ligase in the 
ubiquitination process is revealed only recently (31, 32). Ro52 called also TRIM 21 
mediates ubiquitination of several members of the interferon regulatory factor transcription 
factor family, thereby regulating cytokine production (39-42). RING-dependent 
autoubiquitination of Ro52 was demonstrated in vivo and in vitro, and overexpression of 
Ro52 in stably transfected B cells leads to decreased proliferation and increased 
sensitivity to CD40-mediated cell death, suggesting a biological role for Ro52 in cell growth 
and/or apoptosis (31).  
Ro60 is complexed with small non-coding cytoplasmic (Y) RNAs. It has been 
demonstrated that the protein binds misfolded, defective, non-coding RNAs  that are 
eventually degraded (43-45), suggesting a function in a quality control pathway in which 
incorrect folded and otherwise imperfect non-coding RNAs are targeting for decay (46, 47).  
The SSB/La antigen (Figure 1) is a single 48 kDa nuclear phosphoprotein that binds  many 
newly transcribed non-coding RNAs, including Y RNAs (47). There is accumulating 
evidence that La is necessary for correct folding of many small RNAs, suggesting an RNA 
polymerase III transcript maturation role for this protein (48). 
 
1.3.2 Anti-SSA/Ro and anti-SSB/La antibodies 
Several studies aimed to identify antibody specificities associated with CHB, have been 
performed. Although the data vary among the different studies, depending on the method 
used for the detection of the antibodies and the criteria chosen to enroll the patients, most 
of them demonstrate that the risk is higher in women in whom the anti-Ro activity is 
targeted to the 52 kDa component of the antigen rather than to the 60 kDa component (49-
51), especially in those women in whom the antibody response is directed to an 
immunodominant region against the amino acids 200–239 (p200) of the 52 kDa protein 
(50, 52). In a prospective study in which Doppler echocardiography was performed weekly 
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during susceptibility weeks 18–24 in Ro52-positive women, mothers with higher anti-p200 
levels had fetuses with significantly longer AV time intervals (50). The p200 peptide 
encompasses a functional domain, a leucine-zipper structure. Association with 
autoantibodies specific for a functional domain is not a unique feature for congenital heart 
block. In the case of heart block binding of anti-p200 autoantibodies might possibly 
mediate inhibition or decrease the functional activity of the antigen, as is evident for 
autoantibodies against RNA polymerase I inhibiting RNA synthesis, or against DNA 
topoisomerase I causing relaxation of super-coiled DNA (53). Furthermore, is 
demonstrated that cardiac conduction disturbances are associated with moderate to high 
levels of anti-Ro antibodies (50, 54). So, both the fine specificity and the levels of maternal 
anti-Ro52 antibodies are of importance in predicting fetal outcome.  
Antibodies to Ro60 and La have been suggested to have a minor role in predicting the 
fetal clinical outcome in anti-Ro and anti-La antibody–positive mothers (50, 55, 56), 
although an association also between these autoantibodies and the incidences of 
congenital heart block has been demonstrated (55, 57). The level of antibodies to the La 
protein has been found to be higher in mothers of children developing cutaneous lupus 
rather than heart block (55). Although congenital heart block may develop independently of 
maternal antibodies against Ro60 and La, their presence, might be able to amplify the 
immunological response after onset in affected fetuses (58).  
 
1.3.3 Other autoantibodies 
Given the low risk for the development of CHB in anti-SSA/Ro and or anti-SSB/La positive 
mothers other antibodies directed to several other targets then Ro and La proteins, have 
been suggested to be associated with development of CHB. Antibodies against neonatal 
heart muscarinic acetylcholine receptor (mAChR) have been demonstrated to have a role 
in the disease supported by in vitro studies when is reported the binding, and biological 
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effects of these antibodies in CHB (59, 60). Calreticulin, a calcium binding, multifunctional 
protein, involved in calcium storage has been suggested a target in the disease initiation, 
and antibodies to calreticulin have been demonstrated in sera from mothers with affected 
children (61). Another suggested antibody specificity associated with congenital heart 
block is antibodies to p57, which was identified in a child with the disease (62). Antibodies 
to a cleavage product of α-fodrin has, in addition to being identified as an organ-specific 
antibody in SS, been suggested as an additional serologic marker in congenital heart block 
(63). Moreover, the role of antibodies to α-enolase in the development of CHB has been 
investigated, but a relationship was not founded (64).  
 
1.4 Etiopathogenesis 
Direct evidence for a pathogenic role of maternal anti-SSA/Ro and/or anti-SSB/La 
antibodies and especially anti-Ro52 antibodies in CHB comes from experimental studies of 
heart block, both in vitro and in vivo. The presence of anti-SSA/Ro antibodies in the 
cardiac tissue of fetuses dying of CHB, together with deposition of complement, fibrosis, 
and calcification, was demonstrated in the early 1980s by several groups (8-10, 18) 
providing the first link between maternal antibodies and pathogenesis of heart block by 
placing the antibodies at the site of injury. 
 
1.4.1 Experimental models of congenital heart block 
In vitro studies demonstrated a direct pathogenic role of antibodies from mothers of 
children with CHB, as perfusion with maternal IgG containing anti-SSA/Ro and anti-
SSB/La antibodies of rat or human hearts isolated with the Langendorff technique, induced 
bradycardia and complete AVB within 15 minutes (65, 66). Affinity-purified anti-Ro52 
antibodies induced the same effects, showing the individual pathogenic potential of anti-
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Ro52 antibodies. Similar results were obtained in Langendorff - perfused rabbit hearts 
exposed to anti-Ro/La antibodies purified from mothers of children with CHB (67, 68).  
In vivo studies demonstrated the pathogenicity of anti-SSA/Ro and anti-SSB/La antibodies 
based on animal models of active immunization of females before gestation or passive 
transfer of antibodies. 
A. Immunization-based models of CHB 
Active models of CHB, in which female mice, rats, or rabbits are immunized with a 
particular antigen before gestation, have make possible to investigate the pathogenic 
potential of specific antibodies toward Ro52, Ro60, or La separately. Miranda-Carus et al 
(69) showed that immunization of BALB/c mice with Ro60 or La led to the development of 
first-degree AVB in 19% and 7% of the offspring, respectively, and similar results were 
observed in C3H/HEJ mice by Suzuki et al (70). In the study by Miranda-Carus (69), 
immunization of BALB/c mice with the human or mouse Ro52 protein induced first-degree 
AVB in only 9% of the offspring; instead Boutjdir et al (66) demonstrated a 25% incidence 
in the same model. Both studies reported higher degrees of AVB but a lower frequency, 
3.5% to 10% of AVB II/III. Immunization of rats with the human Ro52 protein led to the 
development of first-degree AVB in 10% to 45% of the pups, depending on the strain (71). 
Immunization of rabbits with the human Ro52 protein also induced first-degree AVB in 
12% of the offspring, moreover the authors reported a large number of neonatal deaths, 
which might have been related to higher degree blocks; however, no histological 
evaluation of neonatal hearts was performed to support this hypothesis (72). Salomonsson 
et al (52) showed that immunization of DA (Dark Agouti) rats with the Ro52/p200 peptide 
led to the development of first-degree AVB in 20% (10/52) of the offspring. Immunization of 
mice with a recombinant Ro52β protein (Ro52 isoform lacking exon 4) induced first-degree 
AVB in 12% and AV block II/III in about 6% of the pups (72); however, the relevance of 
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these findings is uncertain as the endogenous protein has never been detected in humans 
or rodents, despite a report of Ro52β mRNA expression in the fetal human heart (73). 
B. Antibody transfer-based models of CHB 
In a study by Mazel and colleagues (74), transfer of affinity-purified anti-SSA/Ro and anti-
SSB/La antibodies from two mothers of children with CHB into pregnant female BALB/c 
mice induced first-degree AV block in 47% to 90% of the offspring, depending on the day 
of gestation at which the injection was performed. Sinus bradycardia was also observed, 
albeit in a somewhat smaller proportion of pups. However, the use of a mixture of anti-Ro 
and anti-La antibodies in this study did not allow the precise identification of the antibody 
specificity contributing to the development of heart block. Ambrosi et al (75) in attempt to 
find the specificity of anti-Ro52 antibodies inducing heart block established a heart block 
model based on the transfer of anti-Ro52 monoclonal antibodies during gestation. Using 
this model, the authors observed that anti-Ro52 antibodies specific for the p200 part of the 
protein induced AVB in the offspring but that antibodies targeting other domains of Ro52 
did not (75). In addition, anti-Ro52-p200 antibodies were shown to disturb calcium 
homeostasis in cultured neonatal cardiomyocytes, supporting a pathogenic role for anti-
Ro52 p200 antibodies in CHB (52). It is worth noting that first-degree AV block developed 
in 100% of the rat pups exposed to the antip200 monoclonal antibodies in utero but that 
only 19% of pups born to females immunized with the Ro52-p200 peptide were shown to 
develop AV block in a previous study. This was interpreted as a sign of the importance of 
the specificity and level of the antibodies in induction of CHB, as the specificities and 
levels induced by immunization were variable, while the monoclonal transfer model 
exposed all pups to the same specificity - and at the same concentration. 
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1.4.2 Proposed hypothesis for CHB  
Despite the observation of a direct role for maternal antibodies in inducing CHB both in 
vitro and in vivo, the mechanisms involved remain unclear. Based on the facts that there is 
no convincing evidence that maternal antibodies can cross the sarcolemma of a normal 
cardiomyocyte and bind  to the Ro52, Ro60, and La proteins, which are the major targets 
of maternal autoantibodies associated with CHB; two categories of mechanisms, not 
mutually exclusive and each supported by experimental data, have been put forward. The 
first is the abnormal surface expression of intracellular Ro⁄La antigens, and the second is 
the cross-reactivity of maternal antibodies with targets other than Ro⁄La antigens. To 
explain the pathogenesis of CHB based on these two categories of mechanisms, three 
major hypotheses have been proposed: the apoptosis hypothesis [cell-surface expression 
of the Ro⁄La antigen] (76), the serotoninergic hypothesis (77) and the Ca channel 
hypothesis [cross-reactivity of maternal antibodies with cell-surface receptors and Ca 
channel proteins, respectively] (78). 
A. Apoptosis hypothesis 
 
The apoptosis hypothesis proposes abnormal (opsonization) surface expression of 
intracellular Ro ⁄ La antigens that become accessible to circulating maternal antibodies on 
the surface of the cardiac myocytes. It is suggested that opsonization converts the 
physiologic process of apoptosis to circumstances in which an inflammatory component is 
evoked (79). Miranda et al., (69, 79) demonstrated that induction of apoptosis results in 
surface translocation of Ro⁄La antigens in human fetal cardiac myocytes. To examine 
whether antibodies reactive to Ro⁄La antigen system indeed bind to the surface of human 
fetal myocytes and to assess the consequences of this surface bindings, the authors used 
biotinylation of cell-surface proteins, scanning electron microscopy of immune gold 
labelled cells and examined the consequences of the release of the inflammatory cytokine 
(79). They confirmed that induction of apoptosis results in surface accessibility of all Ro⁄La 
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antigens for recognition by tumor necrosis factor (TNF) from macrophages co-cultured with 
apoptotic fetal cardiac myocytes. It was concluded that opsonized apoptotic fetal cardiac 
myocytes promote an inflammatory response by macrophages causing damage to 
surrounding conducting tissue. Clancy et al. (80) demonstrated that healthy fetal 
cardiocytes are involved in physiologic clearance of apoptotic cells and that surface 
binding by anti-SSA ⁄ Ro and anti-SSB ⁄ La antibodies inhibits the uptake of apoptotic cells 
by the healthy cardiocytes. The result is accumulation of apoptotic cells promoting further 
inflammation and subsequent scarring. It is, however, difficult to correlate the earlier 
findings to AV conduction abnormalities seen in CHB because the experiments were 
performed in ventricular myocytes, not in conduction system myocytes such as AV node 
myocytes. However, evidence for the subcellular translocation of La autoantigen during 
physiologic apoptosis in the fetal mouse conducting system has been provided (81). Other 
experimental evidence has been proposed to account for the translocation of Ro ⁄ La to the 
cell surface, including viral infection (82), UV light and interferon (IFN) treatment (83). 
B. Serotoninergic hypothesis 
 
Accessibility of intracellular target antigens to circulating maternal antibodies remains a 
challenge. This lead to the consideration of alternative hypotheses such as cross-reaction 
between one or any of the Ro⁄La components and a cell-surface cardiac receptor and ⁄ or 
channel. Indeed, support for this second hypothesis is the report by Eftekhari et al. (77) 
that antibodies reactive with the serotoninergic 5-hydroxytryptamine (5-HT4 receptor), 
cloned from human adult atrium, also bind 52-kD Ro. Moreover, affinity-purified 5-HT4 
antibodies antagonized the serotonin-induced L-type Ca channel activation in human atrial 
cells (77). The finding that functional beta-adrenoceptors in experimental animals appear 
late in the gestation stage, makes this hypothesis more intriguing, because 5-HT4 
receptors could functionally replace the beta-adrenergic receptor during development. Two 
peptides in the C terminus of 52-kD Ro, aa365–382 and aa380–396, were identified that 
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shared some similarity with the 5-HT4 receptor. The former was recognized by sera from 
mothers of children with neonatal lupus and it was this 52-kD Ro peptide that was reported 
to be cross-reactive with antibodies to peptide aa165–185, derived from the second 
extracellular loop of the 5-HT4 receptor (77). These findings are of particular importance, 
because over 75% of serum from mothers whose children have CHB contains antibodies 
to 52-kD Ro. Given the intriguing possibility that antibodies to the 5-HT4 receptor might 
represent the hitherto elusive reactivity that could directly contribute to AVB, Buyon et al 
(84) tried to determine the prevalence of anti-5-HT4 antibodies in mothers whose children 
have CHB. Although, the Authors (84) demonstrated mRNA expression of the 5-HT4 
receptor in the human fetal atrium the electrophysiologic studies established that human 
fetal atrial cells express functional 5-HT4 receptors they failed to find reactivity to 5-HT4 
receptors (84).  
C. Ca channel hypothesis 
The formulation of Ca channel hypothesis was driven by the fact that AV node electro 
genesis is under the control of L-type Ca channel, which is responsible for conduction 
between the atria and the ventricle. Inhibition or blockade of this channel ultimately leads 
to AV block reminiscent of conduction abnormalities seen in CHB. The Ca channel 
hypothesis states that circulating maternal antibodies recognize L-type Ca channel pore-
forming protein a1-subunit to which they bind and prevent Ca ions from entering the 
myocyte (78). Consequently, conduction of the SA impulse through the AV node to the 
ventricle will be hampered leading to delay in conduction or worst to complete AV block.  
Two L-type Ca channels expressed in the heart are Cav1.2 (a1C) and Cav1.3 (a1D). 
Cav1.2 or a1C is ubiquitously expressed in the heart and essentially mediates cardiac 
excitation–contraction coupling. Cav1.3 or a1D, on the other hand, is restricted to the 
supraventricular tissue in the adult with the highest expression in the SA node and AV 
node.  
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Boutjdir et al (65, 72, 85-87) have demonstrated that IgG purified from mothers of children 
with CHB inhibit the ICa-L by 62%, 46.2% and 51% in ventricular myocytes, SA and AV 
nodal cells, respectively, meanwhile had no effect on the transient outward K current the 
delayed rectifier K current and the fast Na current indicating specificity for Ca channels. 
Experimental data supporting a possible cross-reactivity of maternal anti-Ro/La antibodies 
with the α1C and α1D calcium channel subunits have been provided by the same group 
(85-88). In particularly has been shown that the Ca channel a1D subunit is expressed in 
human fetal hearts (87). Furthermore, has been demonstrated that a fraction of sera from 
mothers of children with congenital heart block react to the extracellular loop of the calcium 
channel a1D subunit and that these maternal antibodies can inhibit a1D calcium currents 
in vitro (88). A chronic effect of maternal antibodies on the fetal heart has been proposed 
to be mediated by binding of antibodies to calcium channels and subsequent 
internalization and degradation, leading to not only inefficient signal conduction but also 
insufficient excitation-contraction coupling and reduction of cardiac contractile function 
(72). In support of this hypothesis, mouse pups transgenic for the L-type calcium channel 
subunit Cav1.2 were found to develop AV block and sinus bradycardia at a lower 
frequency than non-transgenic littermates following in utero exposure to anti-Ro/La 
antibodies in an immunization model (89, 90). In addition, mouse pups in which the Cav1.3 
subunit of the L-type calcium channel has been genetically knocked out exhibit first-degree 
AV block, nonetheless at a low frequency, and the occurrence of AV block is increased 
following immunization of females with the Ro and La protein before gestation (88). 
Although this study does not prove that maternal anti-Ro/La antibodies directly cross-react 
with subunits of the L-type calcium maternal autoantibodies exert their pathogenic effects 
at least in part by affecting calcium homeostasis in the heart and disrupting the cardiac 
electric and contractile functions. In addition Salomonsson et al (52) demonstrated that 
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p200-specific anti-Ro52 antibodies dysregulated calcium oscillations of spontaneously 
beating cardiomyocytes in culture.  
 
Figure 3. A two-phase model for the development of congenital heart block.(Ambrosi and Wahren-Herlenius. 
Arthritis Research & Therapy 2012). 
 
Along with, these data support the hypothesis that maternal anti-Ro52 antibodies may 
cross-react to a fetal cardiac molecule involved in calcium regulation and initiate cardiac 
conduction disturbances, detected as first-degree AVB. It is possible that prolonged 
disruption of cardiac calcium homeostasis leads to increased apoptosis in the fetal heart 
(52) is then accompanied by exposure of the intracellular Ro and La proteins and 
subsequently the opsonized apoptotic debris engulfed by macrophage may lead to 
production of pro-inflammatory and pro-fibrotic cytokines which, together with antibody 
deposits and recruitment of complements component, will generate a sustained 
inflammatory reaction in the fetal heart, eventually leading to a permanent damage and 
complete CHB (Figure 3). 
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1.4.3 Maternal and fetal susceptibility factor for congenital heart block  
 
Since 1980s the anti-SSA/Ro and anti-SSB/La have been associated with CHB. However, 
the incidence of CHB is estimated to be only 1-2% CHB of anti-SSA and/or anti-SSB 
positive primigravid women (24) and carries a recurrence rate around 20%, in subsequent 
pregnancies despite the persistence of the autoantibodies (25) suggesting that antibodies 
are necessary but not sufficient to provoke autoimmune-associated CHB and other 
maternal and/or fetal factors may be involved in the susceptibility to CHB. 
There are several reports of dizygotic twins discordant for disease suggesting that there 
may be a genetic fetal factor involved in susceptibility to CHB (2, 25, 91-93). There are, 
also reports of discordant disease expression in monozygotic twins (94) and in 
ovodonation pregnancy (95) indicating that not only fetal genetics are responsible for 
induction of disease.  
Genetic polymorphisms influencing fetal susceptibility to CHB in anti-SSA/Ro and/or anti-
SSB/La-positive pregnancies were first investigated in a group of 40 children with CHB by 
using a candidate gene approach, focusing on two known polymorphisms of the genes 
encoding the pro-inflammatory and pro-fibrotic cytokines tumor necrosis factor-alpha 
(TNFα) and transforming growth factor-beta (TGFβ). The TGFβ polymorphism assessed 
was found significantly more frequently in children with CHB than in their unaffected 
siblings, whereas the TNFα polymorphism studied was found at an increased frequency in 
both affected and non-affected children in comparison with healthy controls (96). Recently, 
the same group (97) performing a genome-wide association study of individuals who have 
CHB and who were born to anti-SSA/Ro and/or anti-SSB/La-positive mothers 
demonstrated a significant association with polymorphisms in the HLA region and at the 
location 21q22 addressing a role of the identified SNPs in susceptibility to CHB. Recently, 
Strandberg and colleagues (71), using congenic rat strains and a Ro52 immunization 
model of heart block demonstrated an influence of both maternal and fetal MHC genes in 
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the development of CHB. The authors (71) showed that maternal MHC restricts generation 
of pathogenic anti-Ro52 antibodies and that the fetal MHC locus regulates susceptibility 
and determine the fetal disease outcome in anti-Ro52-positive pregnancies. Maternal and 
fetal factors other than genetic differences have also been suggested to contribute to the 
development of heart block. Although neither fetal gender nor maternal disease severity 
has been associated with CHB (98, 99) it has been proposed that maternal age may have 
an influence on the outcome of anti-Ro52-positive pregnancies (100). Ambrosi et al (4) in a 
population-based study, found that the risk for CHB increased with maternal age but was 
not influenced by parity. It is also possible that the increasing risk for heart block with 
increasing maternal age reflects the appearance or increased serum levels of anti-Ro/La 
autoantibodies in women over time. The authors (4) found, also, that the seasonal timing 
of the pregnancy influenced the outcome. There was an increased proportion of affected 
pregnancies among all pregnancies for which the susceptibility weeks (18 to 24 weeks of 
pregnancy) took place during the late winter season in Sweden. Whereas an association 
between the winter season, decreased sun 
exposure, and vitamin D levels comes readily to mind, other events linked to the winter 
season, such as viral infections, may also influence the development of heart block. 
Indeed, maternal infections occurring during pregnancy have been suggested to play a 
role in CHB, and a recent report by Tsang and colleagues (101) described cell surface 
exposure of the Ro antigen in fetal cardiomyocytes following cytomegalovirus infection. 
So, this clinical and experimental data suggest that CHB pathogenesis represents a 
complex interplay between immunologic, genetic, and environmental factors (Figure 4).  
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Figure 4. A model for the pathogenesis of CHB. Maternal MHC genes and maternal age determine the 
specificity of anti-SSA/Ro and anti-SSB/La antibodies. These specific antibodies in the presence of  
environmental factors and susceptibility fetal genes determine the initiate of immune process leading to 
inflammation, calcification and fibrosis. (Adapted from Ambrosi and Wahren-Herlenius. Arthritis Research & 
Therapy 2012). 
 
 
1.5 Cardiac involvement in neonatal lupus 
 
CHB was the first cardiac manifestation of NLS, described more than a century ago (15). 
Subsequently antibodies and complement deposits together with signs of fibrosis and 
calcification were described in the conduction fetal system as well as in the entire 
myocardium (8-10), suggesting the potential involvement of maternal autoantibodies in 
other cardiac manifestations of NLS (11-14). 
 
 
1.5.1 Electrophysiological involvement 
The conduction system in the human heart consists on sino-atrial node (SA node), the 
atrio-ventricular node (AV node), the His Bundle and branches and the Purkinje fiber 
(figure 5).  
SA node situated in the right atrium is the principal pacemaker of the heart. The SA node 
generates the electrical impulse, which spreads rapidly over both atria, causing them to 
contract simultaneously. The AV node is the only electrical connection between atria and 
anti-Ro52/p200 
antibodies 
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ventricles. Its function is to transmit the electrical impulse from the atria to the ventricles, in 
order to contract the latter. 
 
Figure 5. Conduction system in the human heart. 
A. Atrio-ventricular block 
The congenital atrio-ventricular block (AVB) is the most common and most recognized 
cardiovascular manifestation of NLS. An AVB is a block or delay in the signal conduction 
through the heart. It is hypothesized that CHB progresses gradually from a first-degree 
AVB to a second-degree AVB and finally this could progress to the irreversible third-
degree AVB (7). In the first-degree AVB all the impulses are conducted from the atria to 
the ventricles, but there is a prolonged interval between the atrial and ventricular 
contraction (the AV-interval), beyond the upper limit of normal. The second-degree block 
refers to a failure to conduct some, but not all, atrial impulses to the ventricles. There are 
several types of second-degree block. In Mobitz type I (Wenckebach) second-degree AVB, 
there is a progressive lengthening of the AV conduction, until an isolated impulse is 
blocked. Mobitz type II second-degree AVB is characterized by a sudden block of an 
isolated impulse without prior lengthening of the AV conduction time. In 2:1 second-degree 
AVB, only every second atrial impulse is conducted to the ventricles. In third-degree AVB 
or complete AVB (CAVB) there is no AV conduction at all, and the atria and ventricles beat 
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independently. Ventricular rates in CAVB are typically between 50-70 beats per minute 
and atrial rates are usually normal (>120 beats per minute). D 
B. Other arrhythmias and conduction abnormalities in NLS 
In addition to AVB, several other electrophysiological abnormalities have been reported in 
the fetus and infant with maternal autoimmune-mediated cardiac disease. These 
abnormalities include both transient and persistent sinus node dysfunction, long QT 
interval, ventricular and atrial ectopy, ventricular and junctional tachycardia, and atrial 
flutter. Although several case reports and small case series have identified several 
arrhythmias and conduction abnormalities associated with AVB by foetal 
echocardiography, the frequency with which these rhythm and conduction disturbances 
occur has been appreciated best by foetal magnetocardiography (102). Recently,  has 
suggested that fetal AVB is far more complex than previously appreciated with complex 
changing rhythms, variable atrio-ventricular conduction in second-degree AVB, abnormal 
QRS waveforms, co-existence of junctional and ventricular ectopy, and atrial and 
ventricular rate responsively in complete AVB (102). 
 
1.5.2 Myocardial involvement 
Although CHB is well tolerated in fetuses and neonates, has been shown that 15–20% of 
affected fetuses develop more diffuse myocardial disease before birth and others may 
clinically manifest myocardial dysfunction after birth despite adequate pacemaker therapy 
(12, 103-105). The echocardiographic appearance of more diffuse disease includes 
ventricular dilation and systolic dysfunction, myocardial hypertrophy, a non-compaction 
appearance to the fetal myocardium in some, and, most commonly, echogenicity of the 
endocardium confirmed in explanted hearts and at autopsy to represent endocardial 
fibroelastosis or EFE (Figure 6) (104, 105).  
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Figure 6. Diffuse endocardial fibroelastosis (Nield et al. JACC 2002.) 
The EFE observed in some is patchy and may involve the crux of the heart, either ventricle 
(right more than left in the fetus and left more than right in the post-natal infant), chordal 
apparatus and papillary muscles and even one or both atria (13, 106). The true incidence 
of more diffuse myocardial disease remains unclear as the proportion of reported patients 
reflects only those with clinically recognized disease at the time of review. Some affected 
infants, for instance, evolve myocardial disease only later in life (12, 104). Moreover, the 
EFE detected echocardiographically often underestimates the degree of EFE based on the 
examination of corresponding pathological specimens (104). The observation of isolated 
EFE and cardiomyopathy, in the absence of conduction abnormalities has suggested that 
the more diffuse myocardial disease represents a separate manifestation of NLS (104). 
Histologically, has been shown maternal autoantibody induced EFE and cardiomyopathy 
to be associated with diffuse disarray of myocardial fibers with IgG deposition in all, IgM 
deposition and even T cell subset activation, the latter findings suggestive of a fetal 
immune response contributing to the disease process (104). Why more diffuse myocardial 
disease occurs in some but not all fetuses and infants with maternal autoimmune-
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mediated CHB remains unclear, but variability in the fetal immune response may 
contribute (104, 107). In addition to myocardial disease, pericardial effusion without other 
signs of hydrops has been reported in some affected fetuses and could suggest the 
presence of pericarditis (108). Finally, recently has been reported an association between 
rupture of the AV valve tensor apparatus and maternal anti-Ro/SSA antibodies as a 
complication of fetal antibody-mediated cardiac inflammation (109). 
 
1.5.3 Structural involvement 
A spectrum of structural heart disease has been reported among fetuses and infants with 
maternal autoimmune mediated cardiovascular disease. In children with maternal 
autoimmune-mediated CHB, structural congenital heart disease has been reported in 16–
42% (92, 110). These lesions have included persistent ductus arteriosus most of which 
have required intervention, and atrial and ventricular septal defects. Of greater interest, 
semilunar and atrio-ventricular valve abnormalities have also been described in 
association with CHB, including stenosis, regurgitation and dysplasia without functional 
changes (92, 110, 111). Inflammation and fibrosis as well as haemodynamic changes 
could potentially contribute to the evolution of at least some of these lesions, as suggested 
in one case of acute chordal rupture with moderate mitral insufficiency in 7-week old infant 
with echocardiographic evidence of EFE involving left ventricular papillary muscles and 
chordae (111). However, the incidence of structural and even functional heart disease 
among infants of mothers with autoantibodies in the absence of CHB is still not certain. 
 
1.6 Diagnosis and monitoring CHB 
CHB is a gradually progressive condition (7) occurring during a critical time period and 
moreover has been observed the efficacy of fluorinated steroids in inhibiting the 
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progression of incomplete block (108, 112-115). Therefore, methods to detect first-degree 
CHB in early pregnancy have been developed. 
 
1.6.1 Foetal electrocardiography 
The fetal electrocardiography (ECG) is based on the acquisition of trans abdominal signals 
consist on individual ventricular depolarizations (QRS complexes). Notwithstanding, this 
technique does not allow identification of individual atrial depolarizations (P waves) (116-
118) and therefore it is no possible to use as a surveillance technique at the moment. 
However, single studies (116, 117) have established reference ranges for cardiac time 
intervals reporting a higher success rate, though suggesting that fetal ECG might be the 
diagnostic tool of choice to detect prolonged PR intervals (119). 
 
1.6.2 Foetal magnetocardiography 
Fetal magnetocardiography has also been used to evaluate the PR intervals. This 
technique defines better than ECG, both atrial and ventricular depolarization’s (120, 121) 
and has provided important information regarding electrocardiographic time intervals, 
repolarization abnormalities (122) and complex rhythms in association with AVB (121), but 
it is expensive, requires a magnetically shielded room and is not suitable for routine 
surveillance of the fetuses. 
 
1.6.3 Foetal echocardiography 
Fetal echocardiography with M-mode and Doppler techniques is the gold standard method 
for prenatal diagnosis of fetal cardiac abnormalities. Using standard ultrasound 
echocardiographic equipment, atrial and ventricular depolarizations are identified indirectly 
by their mechanical [M-mode, Doppler tissue velocimetry (DTI)] or hemodynamic (Doppler) 
consequences. In M-mode, the systolic movements of an atrial wall and a ventricular free 
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wall or the aortic valve are detected. The limit of the M-mode recordings is that the onset 
and maximum of atrial and ventricular contraction is often not clearly defined, making it 
less suitable to diagnose first-degree AVB and even the second-degree AVB (123). Both 
experimental (124) and clinical (125) studies have demonstrated the superiority of the 
Doppler technique compared with the M-mode approach for measuring atrio-ventricular 
(AV) time intervals as a substitute for the electric PR interval in ECG. With Doppler 
technique, the PR interval can be measured recording signals from the mitral valve ⁄ left 
ventricular aortic outflow (MV-Ao) (123), the superior vena cava ⁄ ascending aorta (SVC-
Ao) (124, 125) as well as a pulmonary vein and peripheral pulmonary artery (126). To 
note, all these Doppler techniques are angle dependent, though fetal position frequently 
decides which technique will give the best result. Therefore Sonesson et al (127) have 
also included recordings from the pulmonary trunk and ductus venosus when diagnosing 
foetuses with bradyarrhythmias. Doppler recordings of the ductus venosus are obtained in 
a midsagittal or transverse section as previously described (128). DTI is usually performed 
using an apical view of the atria and ventricles (4-chamber view) to obtain atrial and 
ventricular wall motion velocities for later off line analysis (113, 118). Most frequently, data 
recorded from the right ventricular free wall at the level of the tricuspid valve is used to 
identify the A’ wave as marker of atrial depolarization, and a point corresponding to the 
start of right ventricular isovolumetric contraction to denote ventricular activation (113, 
118). 
All the women positive for anti-SSA/Ro and or anti-SSB/La are followed with weekly 
echocardiography during the critically window of developing CHB and a PR interval>150 
msec is considered pathologic. However, there is a clear need to identify an early marker 
of irreversible cardiac damage and progression to CAVB; there are not performed 
prospective controlled studies to answer this issue. In the multicenter PRIDE study (112) 
comprising 98 Ro⁄SSA antibody-positive pregnancies, the prolongation of the PR interval 
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was uncommon and did not precede more advanced block. The Authors (112) conclude 
that advanced block and cardiomyopathy can occur within 1 week of a normal 
echocardiogram without initial first-degree block. Moreover, echo densities and 
moderate/severe tricuspid regurgitation merit attention as early signs of injury. These 
findings were confirmed by Bergman et al (129) recently in single-centre study of 95 
fetuses. 
 
1.7 Treatment of CHB 
The conventional therapy employed for CHB is fluorinated steroids, such as 
Betamethasone or Dexamethasone, which are only partially inactivated by the placental 
11ß-hydroxysteroid-dehydrogenase complex, and thus have satisfactory bioavailability to 
the foetus. The rationale behind this treatment is to diminish the inflammatory component 
in the foetal conduction system and myocardium and, thus, to reduce cardiac injury. It has 
been demonstrated that steroid therapy could reverse the first degree AVB on a normal 
sinus rhythm (115, 130), but there is no evidence of its efficacy in reversing the 2nd degree 
AVB (112). Moreover it has been shown that the 3rd degree CHB is always irreversible 
(115), but steroid therapy may prevent the fetal complications such as heart failure, 
cardiomyopathy and hydrops related to. 
The number of associated therapies, such as plasmapheresis or intravenous 
immunoglobulins (IVIG), is limited and not thoroughly investigated.  
Plasmapheresis (PF) (Figure 7) removes part of plasma of the patients by means of 
special separators and replaces it with a fluid replacement (4-5% albumine saline, plasma, 
or plasma-expanders). The rationale use of PF in CHB is the removal of pathogenetic 
maternal autoantibodies. PF lowers the levels of anti-Ro/SSA and anti-La/SSB antibodies 
in maternal blood inhibiting their transplacental transfer and preventing the damage they 
cause to the foetal heart. PF has until now been taken into consideration mainly to prevent 
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CHB and there are only few reports concerning its use in diagnosed mothers (108, 131-
136). The procedure has, moreover, always been performed in conjunction with steroids.  
 
Figure 7. Plasmapheresis technique. 
IVIG is a unique immune-modulating therapy that has a wide range of effects on the 
immune system at multiple levels; nonetheless the exact mechanism of action is still 
unclear. Probably IVIG suppress harmful inflammation by a pleiotropic mechanism of 
action (137) that include: anti-idiotype regulation, inhibition of placental transport of 
maternal autoantibodies, accelerated clearance of anti-Ro/SSA and anti-La/SSB 
antibodies and modulation of inhibitory signals on macrophages with consequent reduction 
of the inflammatory response and fibrosis in the foetal heart. When employed as a 
preventive treatment for autoantibody-mediated CHB, it was incapable, at least at the dose 
and timing utilized, to prevent recurrence (138, 139). However, A few attempts have been 
made to treat women diagnosed with CHB utilizing IVIG in conjunction with or without 
steroids (136, 139-141). In all except one of these studies (136) the use of IVIG was not 
systematic throughout the pregnancies, but restricted to a single cycle. There were no 
signs of improvement (139) with the exception of a reversion from a 2nd/3rd degree block to 
a predominant sinus rhythm associated to an intermittent 2nd degree block during one 
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pregnancy with a progression to a 2nd/3rd degree block at birth [140] or were limited to the 
resolution of echocardiographic signs of myocarditis (141). When IVIG were systematically 
employed in conjunction with plasmapheresis and betamethasone beginning from the time 
CHB was detected until birth, two cases of 2nd degree block reverted to normal 
atrioventricular conduction (136).  
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2. AIMS OF THE THESIS 
 
To investigate the epitope specificity of antibodies to the p200 peptide (Part I):  
To explore the role of anti-Ro52 antibodies in the pathogenesis of CHB by identifying the 
epitope specificity of human anti-Ro52-p200 antibodies using mutated human p200 
peptides, rat-to-human p200 mutants and alanin scan p200 peptides.  
 
To develop an animal model of heart block (Part II): 
To study the effect on heart conduction of purified human IgG antibodies from a CHB 
patient mother in an animal model of CHB based on passive transfer of IgG. 
 
To evaluate the efficacy and safety of a combined treatment protocol for CHB (Part 
III): 
The objective was to evaluate the efficacy and safety of a combined therapy protocol 
utilizing weekly plasmapheresis, fortnightly IVIG and daily betamethasone in six cases of 
CHB during pregnancy and IVIG fortnightly in neonates after birth in order to improve 
outcomes in the treatment of this devastating disease. 
 
To investigate the effect of the combined treatment protocol on antibody levels (Part 
IV): 
This study aimed to evaluate the effect of the combine treatment protocol on anti-Ro52, 
anti-p200 and anti-La antibody levels. 
 
 
 
 
 
 Part I 
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EPITOPE SPECIFICITY OF ANTI-Ro52 ANTIBODIES 
 
1. Patient and methods 
1.1 Study population 
Anti-SSA/Ro and/or anti-SSB/La -positive sera from 19 mothers of foetuses with CHB and 
8 babies with CHB attending the Rheumatology Unit of University-Hospital of Padua were 
collected prospectively from 2001-2012 and stored at -80°C.  
 
1.2 Synthetic peptides 
Eighteen different synthesized peptides were used in this study (Figure 8). Peptide 
sequences are illustrated in Figure 9A, 10A, 11A, 13A and 14A. Briefly, human p200 
peptide corresponding to amino acid 200-239 of the human Ro52 protein and containing 
the main CHB related epitope was included, as well as the corresponding rat and mouse 
p200 homologues. Further, human p197 corresponding to amino acid 197-232 and three 
truncated peptides representing N-term, mid and C-terminal parts of the human p200 
peptide were used. Additionally, three peptides based on the rat p200 sequence with 
mutations of crucial amino acids to the residues present in the human sequence were 
included (LEK H8, LEK E18 and LEK E34), Figure 13. Finally, peptides pA233–pA239 
representing an alanine scan with single amino acid residue mutations of the identified c-
terminal epitope of p200 was assayed (Figure 14). N-term, mid, C-term and the LEK 
peptides were synthesized at the Department of Medical Biophysics, Linköping University, 
Linköping, Sweden. All other synthetic peptides were purchased from Thermo 
BioSciences, Ulm, Germany. Peptide purity was confirmed by high-performance liquid 
chromatography and mass spectrometry.  
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Figure 8. Peptides sequences. 
 
1.3 Detection of anti-peptide antibodies 
Anti-peptide antibodies were detected with an in house ELISA as follows: High-binding 96-
well plates (Nunc, Roskilde, Denmark) were coated overnight with 1 µg of peptide diluted 
in carbonate buffer, pH 9.6, per well. Plates were washed three times with PBS/0.05% 
Tween-20 (TPBS) and blocked with 200 µl of TPBS/5% milk powder per well for 1 h. After 
p197   LQELEKDEREQLRILGEKEAKLAQQSQALQELISEL   
p200       LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSS 
N-term      LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSS 
Mid               LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSS 
C-term          LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSS 
LEKH8    LEKDEREQLRILGEKEAELAEKNQALQELISELERRSRGS   
LEKE18    LEKDEREHLRLLGEKEAKLAQQSQALQELISELERRSRGS   
LEK34    LEKDEREHLRLLGEKEAELAEKNQALQELISELDRRCHSS  
r-p200   LEKDEREHLRLLGEKEAELAEKNQALQELISELERRSRGS 
m-p200    LEKDQREYLRLLGKKEAELAEKNQALQELISELERRIRGS  
pA233    LEKDEREQLRILGEKEAKLAQQSQALQELISELARRCHSS   
pA234    LEKDEREQLRILGEKEAKLAQQSQALQELISELDARCHSS   
pA235    LEKDEREQLRILGEKEAKLAQQSQALQELISELDRACHSS   
pA236    LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRAHSS   
pA237    LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCASS   
pA238    LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHAS   
pA239    LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSA 
200 210 220 230
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three washings with TPBS, the plates were incubated with patient sera diluted 1:500 in 
PBS/0.05% Tween-20/1% milk powder for 2 h. Plates were washed three times in 
PBS/0.05% Tween-20 and then incubated with AP-conjugated rabbit-antihuman IgG 
antibody (Dako). Plates were washed again three times, and phosphatase substrate 
tablets (Sigma) dissolved in diethanolamine buffer pH 9.8 was added. Absorbance was 
measured at 405 nm after 2 h. All steps were performed in room temperature except 
coating which was performed at +4°C. 
The specificity and affinity of the antibody to the peptides were analyzed by ELISA in 
competition experiments, including a step of preincubation of diluted sera with peptides in 
concentrations ranging from 0.1-1 mg/ml for 1 h at 20°C prior to analysis in ELISA as 
described above.  
 
1.4 Circular dichroism spectroscopy 
Circular dichroism (CD) spectra of peptides were recorded with an AVIV 62DS 
spectrometer. All spectra were analysed at 25°C over the wavelength range 195–250 nm 
with a step size of 1 nm, a bandwidth of 1.5 nm, an average collection time of 2 s per 
point, an equilibration time of 1 min in a 0.1-cm cuvette. The CD spectra were averaged 
from four wavelengths scans and blanked against the used buffer (0.1% TFA buffer). 
 
1.5 Statistical Analysis 
Statistical analysis was performed using the Mann-Whitney U-test. A p-value <0.05 was 
considered significant. 
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2. Results  
2.1 Specificity of anti-Ro52 antibodies for p197 and p200 peptides 
The human Ro52-p200 peptide has previously been described to contain the main epitope 
of CHB-related pathogenic antibodies. To identify the epitope/epitopes bound by sera from 
mothers of children with CHB within this 40 aa peptides several different strategies were 
used. First, reactivity to peptide p200 and peptide p197 with a high overlap but differing in 
the C- and N-terminal ends was analyzed (Figure 9A). Sera from mothers of babies with 
CHB (Figure 9B) and of the babies with CHB (Figure 9C) showed a significantly higher 
reactivity towards p200 than to p197. The difference in antibody binding to p200 and p197 
could be explained by either sequence differences and thereby lack of amino acids 
forming the epitope or by structural differences in their secondary structure as was 
reported previously (143). Studying the secondary structure with CD was demonstrated 
that p200 has a substantially higher α-helical contribution than p197 (143).  
 
2.2  Reactivity of anti-p200 antibodies to mutated p200 peptides  
To understand whether the difference in binding of CHB sera to p200 and p197 peptides 
depended on sequence or folding differences three truncated peptides representing 
different parts of p200 were synthesized. N-term, mid and C-term peptides were derived 
from the p200 sequence, with the N-term peptide lacking 15 aa in the 3’ terminal of the 
peptide and 4 in the 5' end, the mid peptide lacking 7 and 13 aa respectively in the 3’ and 
5’ terminal of the peptide and the C-term peptide lacking 22 aa in the 5’ terminal of the 
peptide (Figure 10A). To investigate how anti-p200 antibodies from patient sera reacted 
with the mutated synthetic peptides, sera from mothers of children affected by CHB and 
babies with CHB were analyzed. The profile of reactivity was surprisingly similar. The 
mean value levels are reported in Figure 10B. Interestingly, the deletion of amino acids in 
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 the C-terminal of p200 completely abolished the p200 reactivity, while the deletion of 
amino acids in the N-terminal only slightly decreased the p200 reactivity, thus supporting a 
conclusion that amino acids in the C-terminal end of the p200 peptide contain the 
dominant epitope. 
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Figure 9. (A) The p197 and p200 sequence. (B) The reactivity to p200 and p197 in the CHB mothers (n.19) 
and (C) the reactivity to p200 and p197 in the babies with CHB (n.8).  
 
A 
B 
p197  L Q E L E K D E R E Q L R I L G E K E A K L A Q Q S Q A L Q E L I S E L    
p200         L E K D E R E Q L R I L G E K E A K L A Q Q S Q A L Q E L I S E L D R R C H S S  
  
C 
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Figure 10. (A) The p200 and synthetic mutated peptides structure. (B) Antibody reactivity expressed as the 
mean value levels of both mothers (n.19) and babies (n.8) sera tested against the synthetic peptides.  
 
 
2.4 Reactivity of anti-p200 antibodies to p200 “rat-to-human” peptides 
In the attempt to precisely define the epitope specificity, we took advantage of the fact that 
there is high homology between human, rat and mouse Ro52-p200 sequences (Figure 
11A), but that while CHB sera bind well to human p200, they bind significantly less to rat 
and mouse p200, Figure 11B. Reasoning that peptide folding in p200 homologues was 
likely to be stable and similar to folding of the human p200 peptide, and that this folding 
would not be disturbed if mutations to amino acids occurring naturally in other species 
were introduced, we decided on a strategy for epitope identification introducing mutations 
going from rodent p200 sequence to human p200 sequence at amino acids we predicted 
would affect antigenicity. 
 
A 
p 2 0 0     L E K D E R E Q L R I L G E K E A K L A Q Q S Q A L Q E L I S E L D R R C H S S  
n - t e r m   L E K D E R E Q L R I L G E K E A K L A Q Q S Q A L Q E L I S E L D R R C H S S  
m i d       L E K D E R E Q L R I L G E K E A K L A Q Q S Q A L Q E L I S E L D R R C H S S  
c - t e r m   L E K D E R E Q L R I L G E K E A K L A Q Q S Q A L Q E L I S E L D R R C H S S  
B 
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A 
 
p200       LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSS 
r-p200   LEKDEREHLRLLGEKEAELAEKNQALQELISELERRSRGS 
m-p200    LEKDQREYLRLLGKKEAELAEKNQALQELISELERRIRGS   
 
B 
 
 
 
Figure 11. (A) The h-p200, r-p200 and m-p200 peptides structure. (B) The p200 reactivity in different 
species expressed as the mean value levels of both mothers (n.19) and babies (n.8) sera tested against the 
different peptides.  
 
We chose to start with the rat p200 peptide as the CHB serum binding was low, but the 
sequence more similar to human p200 than for the mouse p200, thus requiring fewer 
mutations for our purpose. The selection of amino acids to mutate was based on their 
chemical properties (charge, polarity or bulky side-chain), and their predicted position 
based on a helical wheel sketching assuming an alpha-helical fold of the peptide (Figure 
12). Three mutated peptides rat-to-human p200 were generated and denoted LEK H8, 
LEK E18 and LEK E34. The peptides were identical to rat p200, with the exception that a 
set of selected amino acids in the N-terminal (LEK H8), mid (LEK E18) and C-terminal 
(LEK E34) were substituted for the respective amino acids of the human p200 peptide 
sequence (Figure 13A).  
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Figure 12. (A) Model of a hypothetical dimer of the 200–239 stretch of Ro52. (B) Schematic helical wheel 
representation of the leucine zipper region of Ro52 [amino acid (aa) 198–240] oriented in a parallel 
homodimerization. 
 
To investigate how anti-p200 antibodies from patient sera reacted with the mutated 
synthetic peptides, sera from mothers of children affected by CHB and babies with CHB 
were analyzed. The profile of reactivity was surprisingly similar, exemplified in Figure 13B, 
although levels in the individual sera varied. We observed that almost full anti-p200 
reactivity was gained with the substitutions in the LEK E34 peptide, including a glutamic 
acid substituted for an aspartic acid in amino acid position 233 (Figure 13B) localized in C-
terminal of the p200 peptide, while there was no gain of reactivity by the substitutions in 
the N-terminal or mid part of the peptide (Figure 13B).  
 
A 
B 
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Figure 13. (A) The p200, r-p200 and synthetic rat-to human p200 mutated peptides sequence . (B) Antibody 
reactivity in a single serum tested against the synthetic peptides. 
 
 
 
Analysis by circular dichroism (CD) confirmed that introduction of the substitutions did not 
disrupt folding of the LEK peptides compared to the r-p200 peptide (Figure 14 e 15). 
These data clearly support the presence of a dominant epitope in the C-terminal of the 
p200 peptide. 
 
p200      LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSS 
LEK H8     LEKDEREQLRILGEKEAELAEKNQALQELISELERRSRGS  
LEK E18     LEKDEREHLRLLGEKEAKLAQQSQALQELISELERRSRGS   
LEK E34     LEKDEREHLRLLGEKEAELAEKNQALQELISELDRRCHSS  
r-p200    LEKDEREHLRLLGEKEAELAEKNQALQELISELERRSRGS   
  
A 
B 
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Figure 14. Secondary structure analysis of the overlapping peptides p200 (A) and p197 (B), of r-p200 (C) 
and of the rat to human mutated peptides LEK H8 (D), LEK E18 (E) and LEK E34 (F).  
 
Figure 15. Secondary structure analysis of the human p200 (hp200) and the p200 rat-to human mutated 
peptides LEK E34 by circular dichroism spectroscopy (CD). The CD spectra of hp200 and LEK E34 are 
obtained at room temperature and pH 7.6. 
A B C 
D E F 
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Finally, to verify the epitope and pinpoint the crucial amino acid/s we performed an alanine 
scan of the C-terminal section of the human p200 peptide. The alanine scan included 
mutated peptides pA233–pA239 that were identical to p200, with the exception that one 
amino acid residue in each peptide (aa 233 in pA233, aa 234 in pA234, etc.) was 
substituted for an alanine in the C-terminal side of p-200 (Figure 16A). Interestingly, we 
observed that the substitution of the aspartic acid 233 in the pA233 peptide abolished the 
antibody binding (Figure 16B), while the other mutations did not affect the binding. This 
mutation at position 233 of the alanine scan (pA233) substitutes the same amino acis 
which was mutated in position 233 of the rat-to human mutated peptide (LEK E34). The aa 
is an aspartic acid and in the helical wheel representation of the leucine zipper it is 
localized on the outer surface of the modeled peptide homodimer (Figure 12A and B). 
Thus it is probably accessible for antibody binding, and we suggest it constitutes the 
crucial amino acid for binding of CHB sera to the p200 peptide. 
 
2.5 Specificity for anti-p200 antibodies for LEK E34 peptide  
To confirm the specificity of anti-p200 antibodies for the aspartic acid at aa position 233 we 
performed inhibition experiments based on preincubation and testing in ELISA. In these 
experiments, the anti-p200 reactivity was decreased by pre-incubation with soluble LEK 
E34 in a concentration-dependent manner (Figure 17) to a degree similar to pre-incubation 
with p200 while pre-incubation with r-p200 and PBS did not decrease the anti-p200 
reactivity. 
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Figure 16. (A) The p200, p197 and synthetic mutated peptides structure. (B) Antibody reactivity expressed 
as the mean value levels of the sera of both mothers (n.19) and babies (n.8) sera tested against the different 
peptides.  
 
 
p197       LQELEKDEREQLRILGEKEAKLAQQSQALQELISEL   
p200      LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSS 
pA233    LEKDEREQLRILGEKEAKLAQQSQALQELISELARRCHSS   
pA234    LEKDEREQLRILGEKEAKLAQQSQALQELISELDARCHSS   
pA235    LEKDEREQLRILGEKEAKLAQQSQALQELISELDRACHSS   
pA236    LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRAHSS   
pA237    LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCASS   
pA238    LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHAS   
pA239    LEKDEREQLRILGEKEAKLAQQSQALQELISELDRRCHSA   
 
 
 
 
A 
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Figure 17. Specificity of the LEK E34 antibody to p200 peptide. Sera diluted 1:2000  were pre-incubated with 
peptide or PBS for 60 min at room temperature before analysis in ELISA with human p200 peptide.  
 
 
3. Discussion 
CHB is a gradually progressive disease (7). So, we need a marker of high predictability to 
identify high-risk pregnancies and allow initiation of treatment at the critical stage to 
prevent irreversible CHB in the fetus. In the attempt to identify the epitope specificity of 
pathogenetic antibodies a set of mutated peptides were developed. 
As previously reported (50), we confirm that antibodies against the p200 peptide of Ro52 
are associated with CHB, whereas almost no antibody response against the largely 
overlapping p197 peptide (aa 197–232) can be detected in sera from the mothers of 
affected children. The difference in binding might be explained by p200 carrying an epitope 
on the differing seven amino acids at the C-terminal although previous investigations could 
not distinguish between this possibility and that of structural disruption and differing folding 
between the peptides. 
To investigate whether the difference in reactivity against the two different peptides was 
due to the non-overlapping part of p200 (aa 233–239), we generated 3 human p200 
mutated peptides, N-term, mid and C-term and interestingly the deletion of amino acids in 
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the C-terminal end of p200 completely abolished the p200 reactivity, suggesting that aa 
233-239 are important for antibody binding as binding occurred in this short and 
assumingly unstructured peptide. To identify the amino acids contributing to the epitope we 
took advantage of the fact that the reactivity against rat and mouse p200 was low despite 
high homology. We generate 3 peptides representing human-to rat p200 mutations, LEK 
H8, LEK E18 and LEK E34. Anti-p200 reactivity was gained in the LEK E34 mutant which 
included a glutamic acid substitution for an aspartic acid in position 233 localized in the C-
terminal of the p200 peptide, while there was no reactivity gain when amino acids were 
substituted in the N-terminal or mid sections. To pinpoint the amino acid/s contributing to 
the epitope we performed an alanine scan of this region by substituting one amino acid at 
a time for an alanine and interestingly the substitution of the aspartic acid in the position 
233 (pA233 peptide) totally abolished the antibody binding. This mutation at position 233 
of alanine scan (pA233) thus substitutes the same aa which was inserted in position 233 of 
rat-to human mutated peptide (LEK E34). Moreover, in competition experiment the pre-
incubation of the sera with LEK E34 peptide block antibody reactivity to p200 to the same 
degree as the p200 peptide itself. Furthermore, investigating the secondary structure of 
the rat-to-human peptides by CD we show that all of LEK peptides increase the structured 
content, confirming that the mutations do not destroy the peptide structure.  
Further, the 233 aa is localized at the outer surface of the leucine zipper helical wheel 
modelled peptide homodimer, suggesting that is readily accessible for antibody binding.  
 
4. Conclusion 
We suggest that the aspartic acid at amino acid residue position 233 of the Ro52-p200 
peptide is crucial in forming the main epitope of the Ro52-p200 peptide bound by CHB-
related human Ro52 antibodies. This specificity might relate to the pathogenic process in 
CHB (addressed in Aim 2), and might be used as a tool to identify high risk pregnancies 
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for CHB. However, it remains to investigate whether this epitope is specific for CHB-
inducing sera, or whether it is also bound by sera from anti-SSA/Ro–positive patients 
without CHB. A difficulty in such analyses is the established low recurrence rate of 10-
20%, demonstrating that pathogenic antibody may well be present without CHB 
development and making prediction based on serology alone difficult. Our results might 
still contribute to identification of an antibody specificity more closely associated with 
development of CHB than previously used markers, and provides the possibility to explore 
the role of this antibody in the pathogenesis of CHB and to generate possible drugs to 
prevent CHB. In fact, we could speculate on the possibility to generate a peptide, which 
binds to and absorb the circulating pathogenetic antibodies to prevent them from entering 
the fetal circulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Part II 
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DEVELOPMENT OF AN ANIMAL MODEL OF HEART BLOCK  
1. Methods 
1.1 Experimental animals 
Dark Agouti (DA) rats (Charles-Rivers, Germany) were kept and bred in the Animal 
Department at the Center for Molecular Medicine at the Karolinska Institutet. All 
experimental protocols were approved by the Stockholm North Ethics Committee. 
 
1.2 Purification of human IgG autoantibodies 
Immunoglobulin fractions containing IgG from one mother with a child with CHB and from 
a healthy control donor were purified from plasma by protein A-Sepharose gel. Shortly, 20 
ml of plasma from the patient and 20 ml from the healthy control were first centrifuged at 
10.000 × g for 10 min to remove any precipitates, and then applied to HiTrap Protein A HP 
columns (GE Healthcare) in a chromatography system (ÄKTA, Sweden) to purify the IgG. 
PBS was used as binding buffer and the elution buffer was 0.1 M citric acid, pH 3.5. The 
eluate was collected in 1.5 ml fractions, and immediately neutralized by adding 150 µl of 1 
M Tris-HCl, pH 9.0 per ml of fraction. Protein concentration was measured by the Bradford 
assay and retained Ro52 binding activity assessed by ELISA.  
 
1.3 Experimental procedures 
1.3.1 Antibody transfer  
Female DA rats, 15 weeks old, were injected intra peritoneally (i.p.) with antibody or 
vehicle on day 7 after mating unless specified otherwise (Figure 18). The pregnant female 
rats were injected with either purified CHB-mother IgG (4 or 2 mg, n=3 and n=3, 
respectively), healthy donor IgG (4 or 2 mg, n=3 and n=3 respectively), CHB-inducing 
mouse monoclonal Ro52-antibody Ab31 (4 mg, n=2) (75) or vehicle (PBS, n=2).  
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Figure 18. Experimental strategy. I.P:=intra-peritoneally FECO=fetal echocardiography; 
ECG=electrocardiogram 
 
1.3.2 Anesthesia procedure 
Adult animals were anesthetized with Isoflurane (Baxter). First, the animals were put in a 
chamber ventilated with an Isoflurane concentration of 3% with air and O2 pressure at 1.5 
l/min for 2 minutes, and then kept on mask and ventilated with an Isoflurane concentration 
at 1-2% with air and O2 pressure at 0.25 l/min.  
 
1.3.3 Ultrasound recordings 
Ultrasound (US) recordings were performed using an S2000 ultrasound system with a high 
density linear probe 18 MHz (Siemens medical solutions, Ultrasound Division, Mountain 
View, CA, USA) at 14 days of gestation (Figure 18), assessing the number of pregnancies 
and if the pups were alive or not. In live pups, Doppler recordings measuring the heart 
 
 
I.P. injections of  
human IgG P 
Mating of rats 
P 
FECO and ECG on new  
born pups 
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rate, atrio-ventricular (AV) time, isovolumetric contraction time (ICT), isovolumetric 
relaxation time (IRT), ejection time (ET) and myocardial performance were performed. 
 
1.3.4 ECG recordings 
Three-lead electrocardiograms (ECGs) were recorded within 24 h of birth on conscious 
non-anesthesized pups using four microelectrodes attached to a body clip (Figure 18). 
ECGs were sampled for 5 s four times a minute, with a sampling rate of 1000 Hz. The 
ECGs were digitalized and analyzed with Pharmlab (AstraZeneca, Mölndal, Sweden). 
QRS complexes were averaged and used to calculate the PR interval. PR intervals were 
corrected for heart rate (HR) variation by expressing them as PR/√RR.  
 
1.4 Blood collection from animals and ELISA assay 
Blood samples were obtained from both mothers and pups. Blood specimens were 
centrifuged at 3000 rpm for 15 minutes and analyzed by ELISA for antibody levels as 
described above (Part I), excepted that rodent samples were incubated with an AP-
conjugated rabbit-anti rat IgG antibody (Dako) or AP-conjugated rabbit-anti mouse IgG  
antibody (Dako). Antibody levels are expressed as OD values x100. 
 
1.5 Statistical Analysis 
Statistical analysis was performed using the Mann-Whitney U-test. A p-value <0.05 was 
considered significant.  
 
2. Results 
2.1 The echocardiography findings in rats fetuses  
With the aim to investigate the effects of human Ro/La antibodies on the fetal heart to 
understand the pathogenesis of CHB, an animal model with assessment of fetal cardiac 
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function both during and after pregnancy was developed. Different doses of purified 
human IgG from a CHB-mother or healthy donor was administered i.p. to pregnant rats at 
GA d7. US and Doppler examinations were performed at approximately 14 days of 
gestation. Significant bradycardia and AV time prolongation were present in the group 
injected with 4 mg patient IgG compared to pups injected with 4 mg control IgG or PBS 
(Figure 19A and B). Moreover, the pups in the group injected with 4 mg patient IgG 
showed a significant prolongation of ICT and ET time compared to the group injected with 
4 mg control IgG (Figure 19C and E). Furthermore, pups in the group injected with 4 mg 
patient IgG had a significantly higher MPI (Figure 19F) than the group injected with 4 mg 
control IgG. It was not possible to compare the data with the PBS group due to the 
absence of available recordings in the experiment. We did not observe bradycardia and/or 
prolongation of AV time (Figure 20A and B) in the group injected with 2 mg patient IgG. 
However, also in this group, with lower injected amount of IgG, a significant prolongation of 
ICT, IRT and ET time (Figure 20C, D, E) compared to the group injected with 2 mg control 
IgG was observed. Also, there was a significant increase of MPI (Figure 20F) with respect 
to the group injected with 2 mg control IgG. It was not possible to compare the data with 
the PBS group due to the absence of available recordings in the experiment.  
We also observed that in the group injected with 4 mg patient IgG one of the rats had nine 
dead fetuses, while there were no dead fetus in the group injected with 2 mg patient IgG. 
Among the rats injected with control IgG, there was only one dead fetus in the group 
injected with 2 mg. 
Significant bradycardia (p=0.008) and AV time prolongation (p=0.01) were present in the 
group injected with 4 mg CHB-inducing mouse monoclonal Ro52-antibody Ab31 compared 
to pups injected with PBS. Moreover, was observed a significant prolungation of ET time 
(p=0.004) too; it was not possible to compare the data regarding ICT, IRT and MPI with 
the PBS group due to the absence of available recordings in the experiment. There was no 
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significant difference in AV, ICT, IRT, ET time and MPI in the group injected with 4 mg 
patient IgG compared with the group injected with 4 mg CHB-inducing mouse monoclonal 
Ro52-antibody Ab31, except a significant bradycardia (p=0.04). 
 
2.2 ECG recordings in the pups of rats  
As shown in Figure 21A the pups from the group injected with 4 mg patient IgG present a 
significant reduction of mean heart rate than the group injected with 4 mg control IgG. 
Moreover, the pups from the 4 mg patient IgG group present a significant prolongation of 
the PR and RR intervals compared with the group injected with 4 mg IgG control sera 
(Figure 21B and C). The pups from the group injected with 4 mg CHB-inducing mouse 
monoclonal Ro52-antibody Ab31 present a significant prolungation of PR interval 
(p=0.0005) compared to the group injected with PBS. Moreover, the pups from the group 
injected with 4 mg CHB-inducing mouse monoclonal Ro52-antibody Ab31 showed a 
significant higher heart rate (p=0.02) then the group injected with 4 mg patient IgG. While 
there was no significant difference on PR and RR intervals between the group injected 
with 4 mg CHB-inducing mouse monoclonal Ro52-antibody Ab31 and the group injected 
with 4 mg patient IgG.  
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Figure 19. Echocardiographic recordings from the pups from 4 mg patient IgG group (n=8), 4 mg control IgG 
group (n=25), 4 mg monoclonal antibody Ab31 group (n=7) and PBS group (n=18); AV=atrio-ventricular; 
ICT=isovolumetric contraction time; IRT=isovolumetric relaxation time; ET=ejection time; MPI=myocardial 
performance index 
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Figure 20. Echocardiographic recordings from the pups from 2 mg patient IgG group (n=14), 2 mg control 
IgG group (n=12), 4 mg monoclonal antibody Ab31 group (n=7) and PBS group (n=18); AV=atrio-ventricular; 
ICT=isovolumetric contraction time; IRT=isovolumetric relaxation time; ET=ejection time; MPI=myocardial 
performance index 
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Figure 21. ECG recordings from pups from 4 mg patient IgG group (n=8), 4 mg control IgG group (n=25), 4 
mg monoclonal antibody Ab31 group (n=7) and PBS group (n=18) (A, B and C) and from pups from 2 mg 
patient IgG group (n=14), 2 mg control IgG group (n=12), 4 mg monoclonal antibody Ab31 group (n=7) and 
PBS group (n=18) (D, E and F); PR/SQRT RR= PR intervals corrected for heart rate variation expressed as 
PR/√RR.  
 
 
 
2.3 The anti-Ro52 reactivity in pups  
 
Pups in both groups injected with patient IgG had significant higher reactivity to Ro52 than 
groups injected with healthy donor IgG (p<0.0001). Surprisingly, the group injected with 2 
mg patient IgG had significant higher levels of Ro52 antibodies than the group injected 
with 4 mg IgG patient sera (p=0.001). This may depending on the timing of blood collection 
from pups before/after suckling. 
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Figure 22. Anti-Ro52 levels of pups of rats immunized with anti-SSA/Ro and anti-SSB/La measured with 
ELISA. 
 
 
3. Discussion 
In this study we demonstrate that injecting pregnant rats with human polyclonal IgG from a 
patient with a child affected with CHB results in bradycardia and in prolongation of AV-time 
in a dose dependent manner.  
In fact the group injected with 4 mg patient IgG presented a significant bradycardia and 
prolongation of AV time together with a decreased cardiac performance due to the 
prolongation of ICT and ET and an the increase of MPI in the US recordings. Moreover, a 
significant bradycardia and a prolongation of PR/SQRT RR and RR intervals in the ECG 
recordings were observed. These results confirm observations in studies of children 
affected with CHB that reported an association between high levels of anti-SSA/Ro 
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antibodies and risk of developing CHB (49, 50, 54). Moreover, a prolongation of ICT time, 
sign of decreased cardiac performance due to the reduction of myocardial contractility, 
was observed by Bergman et al (144) in a large proportion of fetuses of mothers with 
positivity for anti-Ro52.  Also, the authors reported a prolonged AV time in this fetuses 
then in those of negative mothers. So, the similarities of different cardiac measurements 
between our animal model and of those of human studies confirm that it is a really valid 
model capturing many of the features of the human disease, and could be useful for this to 
better understanding the pathogenicity and exploring novel therapeutical approaches of 
CHB. The group injected with 2 mg patient IgG presented only a significant prolongation of 
ICT, IRT and ET together with an increase of MPI in the US recordings; as a consequence 
2 mg patient IgG injection is associated only with a decreased cardiac performance. This 
is probably due to a mild myocardial injury without involvement of the cardiac conduction 
system. These results confirm the findings by Bergman et al (144) showing signs of 
decreased cardiac performance in human fetuses exposed to anti-Ro52/SSA antibody. 
Finally, we did not observe third degree AVB, maybe this has occurred as pups die when 
they develop it and/or maybe we had not the right genotype. We can try different strains in 
the future, perhaps based on what human genetics will identify as susceptibility genes. In 
fact, there has been reported that beside the maternal MHC controlling antibody 
specificity, fetal MHC-encoded genes influence fetal susceptibility to CHB (71, 97). 
 
4. Conclusion 
Our data suggest that an animal model for CHB can be established by a simple technique 
of passive transfer of human IgG from a patient with a child with CHB. This model will be 
useful for exploring and understanding the pathogenesis of CHB induced by human Ro/La 
antibodies and to evaluate novel therapeutic approaches and drugs. Further, data 
obtained in this animal model of CHB suggest that high levels (4 mg) of anti-SSA/Ro and 
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anti-SSB/La antibodies induce bradycardia, AV time prolongation and a decreased cardiac 
performance. Even at low levels (2 mg) these antibodies cause a decrease in cardiac 
performance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Part III 
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EFFICACY AND SAFETY OF A COMBINED TREATMENT PROTOCOL FOR CHB 
 
1. Patients and methods 
1.1 Study population  
Six consecutive cases of anti-SSA/Ro and anti-SSB/La-related CHB; 3 cases with 2nd 
degree CHB and 3 cases with 3rd degree CHB attending the Rheumatology Unit of 
University-Hospital of Padua were treated with betamethasone, plasmapheresis, and IVIG. 
Moreover, the newborns were also treated with IVIG soon after birth and continued until 
maternal antibody levels became undetectable. The human ethics Committee of the 
University of Padua Medical Centre approved the study protocol. The patients were 
informed about the disease risks and had signed a written consent form. 
 
1.2 Transplacental treatment strategy 
A. Maternal Steroid Therapy 
Oral Betamethasone (4 mg/day) was prescribed to pregnant women diagnosed with CHB. 
After delivery Betamethasone was switched to Prednisone (25 mg/day), a therapy which 
was gradually tapered during the following 7 weeks unless the mother’s clinical condition 
required continuous steroid treatment. 
B. Plasmapheresis Treatment Protocol 
Plasmapheresis sessions were performed in the Apheresis Unit of Blood Bank of the 
University-Hospital of Padua. The procedures were carried out using a Cobe Spectra 
(Gambro BCT, Lakewood, Co, USA), a continuous blood cell flow separator, according to 
the following timetable: daily sessions at onset for the first 2 days, and thereafter it was 
performed weekly until the delivery date with the last session coinciding with the day 
before the planned delivery. During each session 70-100% plasma volume was 
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exchanged with 4% albumin saline solution. Anticoagulation was ensured with ACD-A in 
1:12 - 1:15 ratios. Only subcutaneous veins of the arms were used as blood access points.  
C. IVIG Treatment Protocol during Pregnancy 
IVIG infusions (1 g/Kg/day) were scheduled at 15 day intervals rather than on two 
consecutive days every month, the usual timing to treat autoimmune disorders. The 
infusions were administered using that timetable in the attempt to reduce the amount of 
IVIG being removed weekly by the plasmapheresis sessions. The following were 
considered contraindications to treatment: immunoglobulin A deficiency, renal failure and 
previous intolerance/allergy to IVIG. Low dose aspirin (100 mg/day), which was suspended 
a week before the planned delivery, was empirically administered to minimize the IVIG’s 
thrombophilia side effects. 
 
1.3 IVIG Treatment Protocol for Newborns  
Treatment was begun as soon as possible after birth in the event of normal IgA levels and 
positivity to passive maternal antibodies. IVIG infusions (1 g/Kg/day) were scheduled at 15 
day intervals rather than on two consecutive days every month in the attempt to prevent 
blood viscosity and excessive plasma volume build-up in the neonates. Slow infusions 
lasting at least 8-10 hours and opportune hydration throughout the infusion were 
monitored. IVIG sessions were continued on this timetable until passive maternal 
antibodies became undetectable on ELISA assay. However, when the IgG serum level 
was higher than that registered at birth, the IVIG infusion took place once a month.  
 
1.4 Monitoring during Pregnancy 
All the patients underwent a physical examination, foetal ultrasound studies, and routine 
biochemistry testing every 2 weeks from the time therapy was begun until delivery. Foetal 
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echocardiographies were performed weekly starting from the time CHB was detected to 
the end of the pregnancy.  
 
1.5 Detection of antibodies 
Maternal sera were collected at the time CHB was detected and at delivery, and newborn 
sera were collected at delivery and before every IVIG infusion. All samples were tested for 
52 and 60 kd anti-Ro/SSA and anti-La/SSB using commercial ELISA kits (Technogenetics, 
Italy). The results were verified using an in-house counterimmunoelectrophoresis method 
and a commercial line-blot assay (Inno-Lia, Innogenetics, Belgium). 
 
1.6 Statistical Analysis 
Statistical analysis was performed using Spearman’s Rho test.  A p-value <0.05 was 
considered significant. 
 
2. Results 
2.1. 2nd degree CHB 
Case no.1 
A pregnant 32-year-old female was referred to our Rheumatologic Centre in January 2009 
during the 20th week of her first pregnancy because of fetal bradycardia detected by fetal 
ultrasound. The patient had been diagnosed with Sjögren’s syndrome two years earlier. A 
fetal echocardiography carried out at the time of referral confirmed the finding of a second-
degree AV block with a mean ventricular rate of 74 beats per minute (bpm) and a mean 
atrial rate of 142 bpm (Figure 23 A). Fetal cardiac anatomy and function were normal, and 
no pericardial or pleural effusions or ascites were detected. Treatment with 
betamethasone (4 mg/day) and weekly plasmapheresis sessions was started. Two weeks 
later, at the 22nd  week, the mean heart rate increased from 74 bpm to 124 bpm (Figure 
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24) and a fetal echocardiography showed episodes of sinus rhythm (mean rate 160 bpm) 
alternating with a 2:1 second-degree AVB. At the 25th week IVIGs (1 g/kg) were added to 
the therapy regimen. IVIG infusions (Kedrion, Italy) were scheduled at 15 day intervals 
rather than on two consecutive days every month, which is the usual scheduling timetable. 
Just as in a previous protocol (145) the infusions were administered with this timing in an 
attempt to reduce the amount of IVIG that was removed weekly by the plasmapheresis 
sessions. Low dose aspirin (100 mg), which was suspended a week before the planned 
caesarean section, was empirically administered to counteract IVIG-related thrombophilia.  
A normal sinus rhythm (Figure 23 B) was recorded by fetal echocardiography at the 26th 
week. As indicated in Figure 24, serial echocardiographies, performed regularly until the 
time of delivery, confirmed a stable mean heart rate ranging between 148 and 175 bpm 
and a PR interval ranging from 0.110 to 0.125 seconds. 
A caesarean section was planned at the 35th week of gestation because of a mild growth 
restriction and a normal male infant weighting 1905 g was delivered. The infant, who’s 
Apgar score was 8 at five minutes, appeared healthy at birth, and no signs of cutaneous 
lesions were noted after ultraviolet light exposure during the follow-up. His anti-SSA/Ro 
antibody levels (52 and 60 kd) were 95 and 280 units/ml, respectively, while anti-SSB/La 
testing was negative. All standard blood tests, including immunoglobulin (Ig) G, IgA, and 
IgM levels, were normal for his age. ECG monitoring after birth showed a sinus rhythm 
with a first-degree AV block and a mean heart rate of 158 bpm during the first 19 hours 
after birth. At that point a variable Mobitz I AV block appeared on ECG monitoring, which 
was confirmed by an ECG (Figure 25 A).  IVIG therapy (1 g/kg per day on two consecutive 
days) was immediately administered to the newborn to counteract the effects of passive 
maternal antibodies and six days later a sinus rhythm with a first-degree AV block was 
recorded by an ECG (Figure 25 B).  
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Figure 23. M-mode fetal echocardiography recordings. A) At the 20
th
 week, the finding of an second-degree 
atrioventricular (AV) block. B) At the 26
th
 week there was a normal sinus rhythm after five weeks of 
betamethasone, five plasmaphereses, and one intravenous immunoglobulin (IVIG) infusion. a: atrial 
contraction, v: ventricular contraction. 
 
 
 
Figure 24. Mean fetal heart rate during the combination therapy. There is a significant correlation between 
mean heart rate increase and weeks of treatment. B: betamethasone, P: plasmapheresis, IVIG: intravenous 
immunoglobulins, CHB: congenital heart block, NSR: normal sinus rhythm with a first-degree AV block. 
 
This finding was confirmed by a 24-hour Holter ECG. Single IVIG infusions (1 g/kg per 
day) were scheduled at 15 day intervals rather than on two consecutive days every month. 
A 
B 
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This was done in the attempt to prevent blood viscosity and excessive plasma volume 
build-up. IVIGs were continued on this time schedule until the infant was four months old, 
at which time anti-52 kd and 60 kd SSA/Ro antibody levels became undetectable. A Holter 
ECG recently carried out, now a healthy 3 year and a half-old male, identified a sinus 
rhythm with a normal PR interval. 
 
 
 
 
 
 
 
 
Figure 25. (A) An electrocardiogram performed 19 hours after the infant’s birth shows a variable Mobitz I AV 
block. (B)  An electrocardiogram performed after two IVIG infusions shows a sinus rhythm with a first-degree 
AV block. 
 
Case no. 2 
A 33-year-old female was diagnosed with undifferentiated connective tissue disease 
because of dry eyes and the presence of anti-SSA/Ro (52 and 60 kd) and anti-SSB/La 
antibodies. She was not receiving any kind of therapy. A normal heart rate (162 bpm) and 
anatomy were recorded during routine fetal ultrasound performed at the 18th week of 
gestation (Figure 26) of her first pregnancy. At the 20th week a ultrasound revealed 
bradycardia, confirmed by a fetal echocardiography which detected a second-degree AV 
block with a mean ventricular rate of 80 bpm and mean atrial rate of 160 bpm. At that time 
betamethasone was administered at a dose of 8 mg/day for three days and then continued 
at 4 mg/day, but it did not achieve any modification in the heart rate, as demonstrated by 
A 
B 
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the six echocardiographies carried out over the next two weeks. The patient was referred 
to our Rheumatologic Centre in October 2010 during the 22nd week of her pregnancy and 
a fetal echocardiography confirmed a 2:1 AV block and registered a heart rate of 75–80 
bpm (Figure 26). A combination therapy was begun at the 23rd week of that pregnancy 
(betamethasone 4 mg/day, weekly plasmapheresis, and IVIG 1 g/kg every 15 days). The 
regimen was continued throughout the rest of the pregnancy until delivery. At the 24th 
week the mean heart rate began increasing (Figure 26) and at the 27th week an 
echocardiography detected a normal sinus rhythm with a mean heart rate of 171 bpm. 
 
Figure 26. Mean fetal heart rate during the combination therapy. There is a significant correlation between 
mean heart rate increase and weeks of treatment. B: betamethasone, P: plasmapheresis, IVIG: intravenous 
immunoglobulins, CHB: congenital heart block, NSR: normal sinus rhythm with a first-degree AV block. 
 
Serial echocardiographies confirmed the improvement in the fetal heart rate, which 
continued until the 34th week (Figure 26), when a premature rupture of the membranes 
occurred and a 2450 g female was delivered by uncomplicated caesarean section. The 
infant’s Apgar score at five minutes was 9. The infant appeared healthy at birth and the 
results of all standard blood tests, including IgG, IgA, and IgM levels, were normal for her 
age. Anti-52 kd and 60 kd SSA/Ro antibody levels were 559 and 420 units/ml, 
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respectively, while the anti-SSB/La titres were borderline (21.1 units/ml). ECG monitoring 
showed a sinus rhythm with a first-degree AV block. Eighteen hours after birth the infant 
underwent two consecutive days of IVIG infusions (1 g/kg per day) and from that time until 
she was four months old, when maternal anti-52 kd and 60 kd SSA/Ro antibodies became 
undetectable by ELISA, she was administered IVIG at 15-day intervals. A Holter ECG 
recently carried out, now a healthy 23 month-old female, revealed a 1st degree block 
alternating with a 2nd degree Wenckebach type block with a mean heart rate of 94 beats 
per minute (bpm). 
Case no. 3 
In November 2011 a 32-year-old woman in her 30th week of gestation was referred to our 
Centre. The patient had been diagnosed with undifferentiated connective tissue disease 
characterized by Raynaud’s phenomenon and positivity for anti-Ro/SSA and anti-La/SSB 
in 1992. A 3rd degree CHB was detected (with an atrial rate of 154 bpm and a ventricular 
rate of 60 bpm) at the 20th week of gestation, which reverted to a normal sinus rhythm the 
following day in the absence of any treatment. Nevertheless, oral Betamethasone (4 
mg/day) was initiated and continued throughout the remainder of her pregnancy. Twice 
weekly echocardiographic evaluations were scheduled. Short periods (one minute 
duration) of a 2nd degree block were detected during fetal echocardiographies at the 23rd 
and 29th weeks of gestation. During the 30th week of gestation a  2nd degree CHB, which 
was stable for a 30 hour period (with an atrial rate of 155-160 bpm and a ventricular rate of 
67-80 bpm), was registered. Plasmapheresis and IVIG infusions were added to 
Betamethasone therapy. There was a partial recovery characterized by a normal 
conduction alternating with a 2nd degree block over the following three week period. At the 
33rd week of gestation the treatment protocol was intensified in the attempt to achieve a 
stable reversion of the block. Plasmapheresis was performed every 5 days and IVIG 
infusions every 11 days. An intensive treatment was possible as maternal serum IgG 
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levels were always within the normal range. A normal atrioventricular conduction with a 
mean heart rate of 150-165 bpm, which remained stable until delivery, was detected at the 
34th week of gestation. A caesarean section was performed a week later in view of 
intrauterine growth restriction (IUGR) and oligohydramnios. A healthy female infant 
weighing 1730 g (10% le) and with an Apgar score of 9 at 5 minutes was delivered. The 
first postnatal Holter ECG registered a stable sinus rhythm with a normal PR interval and a 
mean heart rate of 140 bpm. Levels of passive 52-60 kd anti-Ro/SSA and anti-La/SSB 
antibodies were 1100, 510, and 1327 U/ml, respectively. IVIG infusions were begun 41 
hours after birth and continued fortnightly. The infant is now 12 months-old, has caught up 
with her full term peers, and a recent ECG showed a normal sinus rhythm a mean heart 
rate of 131 bpm. 
 
2.2. 3rd degree CHB 
Case no. 4  
A 36-year-old woman was referred to our Centre in October 2010 during the 22nd week of 
her sixth pregnancy. Diagnosed with Basedow’s disease in 2003 and with Sjögren’s 
syndrome in 2008, the patient’s obstetric history revealed one normal pregnancy, two early 
spontaneous abortions, and two intrauterine deaths at the 18th and 36th weeks, 
respectively. A normal heart rate and anatomy were recorded at the 18th week of gestation 
during the first fetal echocardiography. Fetal ultrasound at the 20th week of gestation 
showed a normal heart rate. An echocardiography at the 22nd week revealed a 3rd degree 
CHB with an atrial rate of 150 bpm and a ventricular rate of 52 bpm. Cardiomegaly and a 
mild pulmonary valve insufficiency were noted. Combination therapy was begun. 
Throughout the remainder of the pregnancy heart rate and cardiomegaly remained stable 
and there were no signs of heart failure or endocardial fibroelastosis (Figure 27). At the 
33rd week of gestation an elective caesarean section was carried out in view of mild 
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oligohydramnios and growth restriction. A male infant with a birth weight of 1810 g (10% 
le) and an Apgar score of 8 at 5 minutes was delivered. A postnatal echocardiography 
confirmed a 3rd degree CHB with normal systolic function. Passive 52-60 kd anti-Ro/SSA 
and anti-La/SSB antibodies were 726, 901 and 195 U/ml, respectively. IVIG infusions were 
begun 14 hours after birth and continued until, five months later, antibodies were no longer 
detectable at ELISA assays. During that time period the neonate’s heart rate and clinical 
conditions remained stable. A pacemaker was implanted when he was 10 month- old and 
now, at 24 months, he is a healthy infant with a body weigh 50th le and a left ventricle 
ejection fraction (EF) 68%.  
 
 
Figure 27. Mean fetal heart rate during the combination therapy. B: betamethasone, P: plasmapheresis, 
IVIG: intravenous immunoglobulins, CHB: congenital heart block, NSR: normal sinus rhythm with a first-
degree AV block. 
 
Case no. 5  
A 25 year-old woman at the 27th week of her third pregnancy (the previous two were 
normal) was referred to us in April 2011 in view of fetal bradycardia detected during a fetal 
ultrasonography. A fetal echocardiography carried out at that time revealed a 3rd degree 
CHB (with a mean atrial rate of 160 bpm and a mean ventricular rate of 63 bpm) 
associated to cardiomegaly. A fetal block with arthralgias, acrocyanosis and high levels of 
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antibodies to 52-60 kd Ro/SSA and La/SSB (12134, 5494 and 446 U/ml, respectively) led 
to a diagnosis of undifferentiated connective tissue disease. Combination therapy was 
begun immediately and a week later the mean ventricular rate increased to 75 bpm. 
Subsequent weekly echocardiographies confirmed a 3rd degree CHB and showed a further 
increase in the ventricular rate reaching 85 bpm with a regression of cardiomegaly. At the 
35th week a sudden placental abruption took place and a caesarean section was carried 
out. A healthy female weighing 1790 (10% le) with an Apgar score of 8 at 5 minutes was 
delivered. A postnatal ECG confirmed a 3rd degree CHB with a mean heart rate of 85 bpm 
and an echocardiography registered a normal systolic function with no signs of further 
cardiac complications. As expected, the neonate was positive for passive 52-60 kd anti-
Ro/SSA and anti-La/SSB antibodies (829,1347,105 U/ml, respectively), and IVIG infusion 
was begun and continued during the next 6 months until maternal antibodies were no 
longer detectable. Now, at 18th months, the infant enjoys good health. A recent 
echocardiography registered a left ventricle EF 78%. and a Holter ECG showed a mean 
heart rate of 67 not requiring pacing 
Case no. 6  
A 34 year-old woman was referred to our Rheumatologic Centre in April 2011 at her 24th 
week of gestation in view of bradycardia (119 bpm) detected during a fetal sonography 19 
days earlier. The patient reported two previous normal pregnancies and one early 
abortion. An echocardiography carried out a few days later revealed a 3rd degree CHB with 
a ventricular rate of 60 bpm, cardiomegaly, mild insufficiency of the mitral and tricuspidal 
valves, and mild pericardial effusion. The patient was healthy and 52-60 kd anti-Ro/SSA 
antibodies at the time CHB was detected were 94 and 658 U/ml, respectively. Combination 
therapy was begun as soon as the ventricular rate registered between 56 and 60 bpm with 
an atrial rate of 130-150 bpm and the valves and pericardial effusion were stable. At the 
36th week a mild intrauterine growth restriction (IUGR) was registered and a planned 
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caesarean section was carried out. A male infant weighing 2315 g was delivered in good 
clinical condition. His Apgar score was 9 at 5 minutes and an echocardiography, carried 
out soon after birth, confirmed a 3rd degree CHB, without cardiomegaly and with normal 
ventricular function. Passive 52-60 kd anti-Ro/SSA antibodies were detected in his blood 
(43 and 65 U/ml, respectively) and IVIG infusions were administered for 5 months. During 
that period the mean ventricular rate was stable ranging between 57 and 67 bpm and 
control echocardiographies were stable. The infant is now 17th months old and his heart 
rate (stable at 60 bpm) and haemodynamic condition (left ventricle EF 71%) do not require 
pacing. 
 
3. Discussion  
Currently no therapy is found to be effective in the treatment of 2nd and 3rd degree CAVB 
induced by maternal antibodies (146); also because the rarity of the disease does not 
allow for controlled clinical trials.  
The aim of this study was to evaluate the outcome of a combined therapy protocol utilizing 
daily Betamethasone, weekly plasmapheresis, and fortnightly IVIG in six cases of CHB 
during pregnancy and IVIG fortnightly in neonates after birth. The foetuses affected with 
2nd degree block reverted to a normal atrio-ventricular conduction during pregnancy while 
those with a 3rd degree block remained stable (case 4), showed a higher ventricular rate 
(case 5), or an improvement in cardiac function (case 6), which improved their chances for 
survival and delayed the need for a pacemaker. No severe cardiac complications such as 
impaired ventricular function, hydrops or cardiomyopathy were observed in the foetuses 
with 3rd CHB. The follow-up of the children affected with 2nd degree CAVB revealed a 
complete regression of the block in case 1 and 3 and no signs of relevant worsening in 
case 2. It might be that the 2nd degree block of case 2 did not revert to a stable normal 
sinus rhythm because of the late beginning of the combined therapy (136). In fact, for two 
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weeks after CAVB detection only betamethasone was administered to the mother and it 
did not achieve any modification in the heart rate.  The infants affected with 3rd degree 
block (cases 4,5, and 6) remained stable and until now only one has required a pacemaker 
at the age of 10 months. It is also interesting to observe that no side-effect of combined 
therapy was registered in any case. 
The novelty characterizing this therapeutic strategy was the combination of three 
treatments whose effects were exploited to neutralize anti-Ro/SSA and anti-La/SSB 
antibodies and their pathologic effects: a) Betamethasone was used to reduce 
inflammation of the foetal conduction system and the myocardium; b) Plasmapheresis was 
employed to remove a large part of the offending autoantibodies from the maternal-foetal 
circulation; and c) IVIG was used to counteract the remaining autoantibodies. It is also 
possible that IVIG therapy treats foetal cardiac injury thanks to its transplacental passage.  
The idea of continuing IVIG treatment after birth was based on several reports describing 
postnatal progression of incomplete blocks and the occurrence of other cardiac 
complications (135, 140, 141, 147). Our group was first faced with that decision while we 
were monitoring case 1 in this report. After a short period of 1st degree block at birth, after 
nineteen hours he progressed to a 2nd degree Wenckebach type block and therefore the 
decision was taken to prescribe IVIG with a prompt regression to the initial 1st degree 
block. Also employed in the treatment of other neonatal diseases such as alloimmune 
thrombocytopenia, IVIG is, in fact, considered safe therapy for foetuses and neonates. 
Plasmapheresis, instead, cannot be recommended for routine use in neonates because of 
problems connected to vascular access and prolonged steroid therapy could induce 
serious side effects in newborns (148).  
The efficacy of the combination treatment strategy described here is probably connected 
to the precocious timing that was used in these cases. It should, in fact, be begun as soon 
as a 2nd degree CHB is detected and before irreversible and deleterious effects on the 
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atrio-ventricular node tissue have taken place (107). Thus, according to most authors then, 
foetuses exposed to maternal anti-Ro/SSA and/or anti-La/SSB antibodies should be 
carefully monitored by weekly echocardiographies between the 18th and 24th weeks of 
gestation. If this combined therapy is also effective in treating 3rd degree CHB remain to be 
proven. It might well be that blocking the progression of heart injury results in an increase 
of basal heart rate thus delaying the necessity of pace-maker implantation.   In any case 
strict adherence to timing and dosage is a primary determinant of treatment success.  
 
4. Conclusion 
Overall, lessons learned from these case series are: a) the efficacy in treating 2nd degree 
CAVB, and b) the safety of plasmapheresis and IVIG therapies. The low number of treated 
cases, the relatively short follow-up (mean 22.7 months ± 10.4, range 12-42 months) and 
the high cost of the procedure can all be considered limits. If these results are confirmed 
by large-scale studies, this protocol could lead to improved outcomes in the treatment of 
this devastating disease. 
 
 
 
 
 
 
 
 
 
 
 
 Part IV 
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THE EFFECT OF THE COMBINED TREATMENT PROTOCOL ON ANTIBODY LEVELS 
 
1. Patients and methods 
1.1 Study population 
Sera from 6 mothers of foetuses with CHB, attending the Rheumatology Unit of University-
Hospital of Padua treated with the combined therapy protocol were collected prospectively 
from 2009-2012 and stored at -80°C. There were 3 samples collected before, during and 
at the end of the treatment from all the patients, and serial sera before and after each 
plasmapheresis from 4 mothers. The anti-Ro52, anti-p200 and anti-La antibody levels 
were investigated. 
 
1.2 Detection of antibodies 
Anti-Ro52 and anti-p200 antibodies were detected with an in house ELISA as previously 
described (Part I). Anti-La antibodies were detected with a commercial ELISA kit 
(Orgentec, Germany). Anti-tetanus antibodies were detected with an in house ELISA as 
follows: high-binding 96-well plates (Nunc, Roskilde, Denmark) were coated overnight with 
100 µl/well of tetanus 1:250 diluted in carbonate buffer, pH 9.6. Plates were washed three 
times with PBS/0.05% Tween-20 (TPBS) and blocked with 200 µl of TPBS/5% milk 
powder per well for 2 h. After three washings with TPBS, the plates were incubated with 
patient sera diluted 1:500 in PBS/0.05% Tween-20/1% milk powder for 2 h. Plates were 
washed five times in PBS/0.05% Tween-20 and then incubated with AP-conjugated rabbit-
antihuman IgG antibody (Dako) for 2 h. Plates were washed again three times, and 
phosphatase substrate tablets (Sigma) dissolved in diethanolamine buffer pH 9.8 was 
added. Absorbance was measured at 405 nm after 1,5 h. All steps were performed in 
room temperature except coating which was performed at +4°C. 
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1.3 Statistical Analysis 
Statistical analysis was performed using Wilcoxon and two way ANOVA tests. Linear 
regression was performed to evaluate the decrease of antibody levels compared to the 
basal value. A p-value <0.05 was considered significant. 
 
2. Results 
2.1 Anti-Ro52 and anti-p200 antibody levels in women treated with a combined     
therapy protocol 
The effect of the combined therapy protocol on autoantibody levels was analyzed as 
follows. First, we investigated the anti-Ro52 and anti-p200 antibody levels at 3 time points 
during pregnancy (before, somewhere during and at the end of the treatment). 
Surprisingly, we observed that Ro52 autoantibody levels were not affected by the 
plasmapheresis procedure. Anti-p200 levels displayed a moderate decrease, which 
however was significant (Figure 28). 
 
 
 
 
 
 
 
Figure 28. (A) The anti-Ro52 and (B) anti-p200 antibody levels in women treated with the combine therapy 
protocol. 
 
2.2 Antibody levels before and after plasmapheresis 
As plasmapheresis is a well established method to effectively deplete circulating IgG, we 
proceeded to investigate how plasmapheresis affects autoantibody levels. In the next step, 
A B 
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we analyzed the anti-Ro52, anti-p200 and anti-La antibody levels before and after each 
plasmapheresis in four patients treated with the combined protocol. The analysis 
demonstrated that the plasmapheresis procedure indeed did decrease autoantibody levels 
in several patients when comparing samples taken directly before and after a 
plasmapheresis procedure, but also that the effect was very modest in patients with high 
titer autoantibody levels. For example, the levels of anti-Ro52 antibodies significantly 
decreased in patient N.1 (Figure 29A) and patient N.3 respectively, p<0.0001 and 
p=0.004, while they did not decreased significantly in patient N.2 (Figure 29B) and N.4. 
The linear regression shows that the patients with high levels of anti-Ro52 antibodies 
(patient N.2 and N.4) have a less decrease of their levels after plasmapheresis (Figure 
29C). 
The levels of anti-p200 antibodies significantly decreased in all the patients, p=0.0001 
(Figure 29D), p=0.02 (Figure 29E), p=0.008 and p=0.03, respectively. However, the linear 
regression (Figure 29F) shows that the patient with high levels has less decrease of anti-
p200 antibody levels after the plasmapheresis. 
The anti-La antibody levels followed a similar pattern and significantly decreased in patient 
N.1, N.2 and N.3 p=0.0001 (Figure 30A), p=0.04 and p=0.001, respectively; while the 
levels of anti-La antibody did not decreased significantly in patient N.4 (Figure 30B). The 
linear regression (Figure 30C) shows that the patient with high levels has less decrease of 
anti-La antibody levels (patient N.4) after the plasmapheresis. 
 
2.3 The role of IVIG on antibody levels 
All the patient treated with the combine therapy was given IVIG fortnightly and 
plasmapheresis every week as reported in Figure 31.  
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Figure 29. The anti-Ro52 antibody levels in patient N.1(A), patient N.2 (B) and linear regression showing the 
relative decrease of anti-Ro52 antibody levels in the first plasmapheresis (C). The anti-p200 antibody levels 
in patient N.1 (D), patient N.2 (E) and linear regression (F) showing the relative decrease of anti-p200 
antibody levels in the first plasmapheresis. 
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Figure 30. The anti-La antibody levels in patient N.1 (A), patient N.4 (B) and linear regression (C) showing 
the relative decrease of anti-La antibody levels in the first plasmapheresis. 
 
 
 
 
Figure 31. The treatment strategy; P=plasmapheresis; IVIG=intravenous immunoglobulin; WG=week of 
gestation 
 
One possibility for explaining the surprisingly small effect of plasmapheresis on the 
autoantibody levels was that Ro/La antibodies were present in the IVIG infusions. To 
 
IVIG IVIG IVIG IVIG IVIG IVIG IVIG 
P P P P  P  P    P   
 
P 
 - 82 - 
 
exclude this possibility and to investigate the role of the IVIG on the antibody levels we 
evaluate the levels of total IgG before and after each cycle of plasmapheresis.  Figure 32 
illustrate the results from patient 1 who receive the first infusion of IVIG after the ninth 
cycle of plasmapheresis. As expected the levels of total IgG increases after the infusion of 
IVIG and significantly decrease after each plasmapheresis (p=0.0002). 
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Figure 32. The levels of total IgG tested in patient 1;*=IVIG infusion 
 
 
 
As the IVIG is produced by pooling sera from blood donors we analyzed the IVIG (Kedrion, 
Italy) which we infused to our patients for anti-Ro52, anti-p200 and anti-La antibodies. No 
reactivity for either Ro52, p200 or La was observed in the IVIG.  
Moreover, as anti-tetanus is one of the more used vaccine in general population, we 
evaluate patient’s sera reactivity to anti-tetanus antibodies and found that their levels 
increased after infusion of IVIG as reported in Figure 33. Obviously, the IVIG from blood 
donors was positive for anti-tetanus antibodies. The anti-tetanus antibodies were negative 
in one patient who lacked anti-tetanus immunity in samples taken initially obtained anti-
tetanus antibodies after IVIG treatment.  
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Figure 33. Anti-tetanus antibody levels before and after plasmapheresis tested in patient N. 4 ;*=IVIG 
infusion 
 
 
3. Discussion 
In this study we evaluated the effect of the combined treatment on antibody levels. First, 
we investigated the anti-Ro52 and anti-p200 antibody levels in 6 treated patients at 3 time 
points of the pregnancy (before, during and at the end of the treatment) and surprisingly 
we found that only the anti-p200 levels were significantly decreased. In 4 out of these six 
patients serial sera obtained before and after each treatment were available, and we used 
these to evaluate the effect of plasmapheresis on Ro52, p200 and La autoantibody levels 
in detail. As anti-Ro60 antibodies are considered less central in the development of CHB 
(50) we did not detect those antibodies in the study. We found that plasmapheresis 
significantly decrease the anti-Ro52, anti-p200 and anti-La antibody levels in all cases 
except in patient N.2 and N.4 who have the highest levels of anti-Ro52 antibodies and in 
these patients there was not a significant decrease. In fact, a linear regression analysis 
demonstrated that patients with highest autoantibody levels have a less decrease in anti-
Ro52 antibody levels. These results might be explained by the limit of ELISA assay which 
does not have a good resolution for highest antibody levels. Furthermore, as all patients 
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were treated with IVIG infusions we investigated the levels of total IgG before and after 
each plasmapheresis and observed that the levels of total IgG increased after the IVIG 
infusion. As IVIG is produced by a pooling sera from blood donors, we analyzed the anti-
Ro52, anti-p200, anti-La and anti-tetanus antibody reactivity in a sample of the infused 
IVIG to exclude the possibility that the autoantibodies were being infused to the patients. 
We found only anti-tetanus reactivity and no Ro52, p200 or La antibodies within the IVIG. 
These latter results confirm that the changes in antibody levels depend on a) removal of 
pathogenetic antibodies by plasmapheresis treatment and b) novel production by the 
patient. 
 
4. Conclusion 
Our data indicate that weekly plasmapheresis reduces the levels of anti-Ro52, anti-p200 
and anti-La antibodies in patients with lower autoantibody titers, but that it has a modest or 
no effect on autoantibody levels in patients with high titers of autoantibodies. It is not 
known how low autoantibody levels need to be for decreasing the risk of autoantibody-
related pathology in CHB. In fact, there are no scientific evidence that depletion of Ro/La 
antibodies will have a beneficial effect although it is reasonable to hypothesize that it 
would.  
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